Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Category: Advanced Practice Registered Nurses (APRN)

ChiroMedBlogAdvanced Practice Registered Nurses (APRN)

Discover the role of Advanced Practice Registered Nurses (APRN): highly skilled healthcare professionals providing specialized care and improving patient outcomes.

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Gut Health and Hormone Balance Treatment

Abstract

I am Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through the science and practice of optimizing hormones by treating the gut–liver–hormone axis and reinforcing micronutrient and mitochondrial foundations. I explain how dysbiosis, intestinal permeability, and microbial enzymes like beta-glucuronidase reshape estrogen metabolism and influence conditions such as PCOS, endometriosis, and autoimmunity, and how lipopolysaccharide (LPS) and short-chain fatty acids (SCFAs) affect insulin sensitivity, mood, and inflammation. I translate current research on vitamin D, K2, iodine, selenium, methylated B vitamins, DIM, and shilajit into clinic-ready protocols, and I show where integrative chiropractic care fits by supporting vagal tone, motility, neuromusculoskeletal dynamics, and autonomic balance. You will find practical frameworks, dosing concepts, lab-monitoring advice, and rationale for each intervention, with citations to leading researchers.

Why Hormones Are Microbiome-Dependent: The Gut–Liver–Hormone Axis

When I first connected hormone symptoms to gut physiology, I saw a pattern: many “hormone” problems began as microbiome and barrier problems. The gut microbiome—a complex community of bacteria, viruses, fungi, and archaea—regulates digestion, immune tolerance, barrier integrity, and the enterohepatic circulation that clears estrogens. From the earliest studies linking metabolic endotoxemia to insulin resistance, it has become clear that LPS-driven inflammation can disrupt cardiometabolic and reproductive health (Cani et al., 2007).

  • When the microbiome is balanced, commensals generate SCFAs (notably butyrate) that nourish colonocytes, tighten junctions, and reduce inflammatory signaling.
  • When dysbiosis develops, beta-glucuronidase-producing taxa expand, and LPS permeates, amplifying NF-κB cytokine cascades that alter hormone receptors, hepatic detoxification, and insulin signaling (Fasano, 2012; Slyepchenko et al., 2017).

Clinically, if you manage estrogen symptoms, insulin resistance, or autoimmune patterns, you are managing the microbiome—whether you realize it or not.

Dysbiosis and Leaky Gut Explained: Distinct Problems that Reinforce Each Other

Two related but distinct issues commonly coexist:

  • Dysbiosis: A shift away from beneficial microbes, with loss of diversity and expansion of pathobionts. Consequences include increased LPS, altered bile acid signaling, and elevated beta-glucuronidase.
  • Leaky gut (increased intestinal permeability): Disruption of tight junction proteins (occludin, claudins, ZO-1) allows antigens and endotoxins to enter circulation, thereby increasing systemic inflammation and immune activation (Fasano, 2012).

Why that matters for hormones:

  • LPS activates TLR4–NF-κB, increasing TNF-α, IL-1β, and IL-6—cytokines that reduce insulin signaling and alter steroid hormone receptor function (Cani et al., 2007).
  • Permeability increases immune load and oxidative stress, thereby consuming methyl donors and glutathione needed for safe phase II detox (methylation, glucuronidation, sulfation) of estrogens.

I screen for these drivers whenever patients report PMS, heavy cycles, PCOS features, endometriosis pain, acne or hair loss, mood changes, fatigue, or autoimmune flares. Correcting the gut often increases the safety and efficacy of hormone therapy.

Estrogen Metabolism 101: Enterohepatic Circulation and the Estrobolome

The liver metabolizes estrogens via phase I hydroxylation (CYP1A1, CYP1B1) and phase II conjugation (COMT methylation, glucuronidation, sulfation). Conjugated metabolites pass into bile and should be excreted. In dysbiosis, microbial beta-glucuronidase deconjugates these estrogens, promoting reabsorption and recirculation—the biochemical basis of “estrogen dominance,” even with careful dosing (Plottel & Blaser, 2011).

  • 2-hydroxylation generally produces less proliferative metabolites.
  • 4- and 16α-hydroxylation yield more proliferative or potentially genotoxic metabolites if methylation and conjugation are suboptimal.

In complex cases or when there is a family history of estrogen-dependent cancers, I consider urinary metabolite testing to map pathways and guide targeted support.

PCOS, Endometriosis, and Autoimmunity: What the Microbiome Adds

Recent studies sharpen the microbiome’s role:

  • PCOS: Dysbiosis with fewer SCFA producers and higher LPS correlates with insulin resistance, hyperandrogenism, and impaired GLP-1 signaling (Lindheim et al., 2017; Qi et al., 2019). Restoring butyrate producers improves metabolic tone.
  • Endometriosis: Altered microbiota, increased permeability, and immune activation correlate with symptom severity. Increased beta-glucuronidase raises estrogen recirculation that can exacerbate lesions and pain (Chen et al., 2017; Jiang et al., 2017).
  • Autoimmunity: Barrier dysfunction and loss of tolerogenic species permit pathobiont translocation and molecular mimicry, priming autoimmune activity (Manfredo Vieira et al., 2018).

Clinical translation: Addressing the gut can reduce hormone dosing requirements, expand the therapeutic window, and stabilize mood, sleep, and metabolism.

The Simple Question with Big Impact: Are You Pooping Daily?

I ask every patient: “Do you have a daily bowel movement?”

  • Estrogen metabolites exit via bile and stool. Constipation increases residence time, giving beta-glucuronidase more opportunity to deconjugate and recirculate estrogens.
  • Correcting bowel habits is a core risk-reduction strategy for estrogen-driven conditions.

Practical steps I use:

  • Increase hydration and electrolytes.
  • Ramp fiber to 25–35 g/day; add PHGG (partially hydrolyzed guar gum) 4–6 g/day for low-bloat prebiotic support.
  • Add magnesium glycinate or citrate at night for stool regularity and sleep.
  • Encourage postprandial walks and vagal toning (slow exhale breathing, humming).

A 3-by-3 Framework for Gut Repair: Remove, Replace, Repair

To keep things doable, I use a 3-by-3 approach:

  1. Remove/Reduce Irritants
  • Clean up the diet: favor whole foods; limit alcohol, ultra-processed items, added sugars; consider a gluten-light or gluten-free trial for sensitive individuals.
  • Medication review: minimize NSAIDs and PPI overuse when clinically safe.
  • Stress load: hard-wire breath work, walks, and sleep hygiene.
  1. Replace and Restore
  • Fiber and prebiotics: 25–35 g/day total fiber; add PHGG for gentle SCFA support.
  • Probiotics: multi-strain Lactobacillus and Bifidobacterium blends (e.g., L. rhamnosus GG, B. lactis) for barrier and immune balance.
  • Digestive support: bitters and meal hygiene for hypochlorhydria/slow motility; phosphatidylcholine and balanced fats for bile flow.
  1. Repair and Rebalance
  • Barrier repair: L-glutamine 5 g/day, zinc carnosine, N-acetyl-D-glucosamine, omega-3s as indicated.
  • Inflammation control: Berberine for dysbiosis-associated endotoxemia; curcumin and quercetin for NF-κB calming.
  • Lifestyle anchors: 150 minutes/week activity; 10-minute post-meal walks; consistent 7–9 hours of sleep.

Why this approach works:

  • Prebiotics increase SCFAs, reinforce tight junctions, and support T-regs via HDAC inhibition.
  • Probiotics competitively inhibit pathobionts, reduce beta-glucuronidase activity, and enhance mucosal IgA.
  • L-glutamine fuels enterocytes and accelerates barrier recovery.
  • Berberine improves the microbial balance and activates AMPK to improve insulin sensitivity.

Nutrient Foundations for Receptor-Level Hormone Action: D, K2, A, Magnesium, Iodine, Selenium, and Methylation

I frequently see patients with robust serum hormones but poor tissue effects. The missing link is often receptor signaling, cofactors, and membranes.

  • Vitamin D3 behaves like a secosteroid hormone that modulates transcription through the VDR. Low vitamin D is associated with all-cause and cardiovascular mortality and can blunt androgen signaling even when total testosterone appears normal (Pilz et al., 2011; Holick, 2017).
  • Magnesium is a cofactor for D activation (25- and 1α-hydroxylases); deficiency dampens VDR signaling (Rosanoff et al., 2016).
  • Vitamin K2 directs calcium into bone and away from soft tissues by activating matrix Gla protein and osteocalcin; it complements D to protect vessels and build bone (Schurgers & Vermeer, 2000; Beulens et al., 2013).
  • Vitamin A supports epithelial integrity, immune balance, and nuclear receptor synergy with vitamin D.

I often use an ADK formula (D3 with K2 and A) alongside magnesium to safely improve receptor-mediated effects, while monitoring 25(OH)D, calcium, and PTH (Rosen et al., 2012).

Thyroid resilience: iodine and selenium synergy

  • Iodine is essential for T4/T3 synthesis, but safe utilization depends on selenium-dependent enzymes (glutathione peroxidases, thioredoxin reductases) to quench the H2O2 generated during iodide organification (Ventura et al., 2017).
  • Inadequate selenium increases oxidative stress at the thyroid, raising the risk of autoimmunity when iodine intake rises (Gartner & Gasnier, 2003).
  • I pair iodine (200–400 mcg) with selenium (100–200 mcg selenomethionine) and often zinc (10–30 mg), titrated to labs and symptoms (Zimmermann & Boelaert, 2015).

Methylation for estrogen safety

  • Methylated B vitamins—methylfolate and methylcobalamin—support COMT-mediated methylation of catechol estrogens, reducing genotoxic stress and stabilizing phase II clearance.

These micronutrients are the bedrock that allows hormones to “dock” and trigger healthy cellular responses.

DIM and Estrogen Metabolites: Steering Toward Safer Pathways

Diindolylmethane (DIM) shifts estrogen metabolism toward 2-hydroxylation and away from 16α- and 4-hydroxylation pathways associated with proliferative and genotoxic risk (Zeligs et al., 2006; Reed et al., 2006). Preclinical studies suggest that DIM may also upregulate BRCA1 signaling and promote apoptosis in cancer cell lines (Fan et al., 2009; Li et al., 2010).

How I apply it:

  • Women with estrogen-dominant symptoms or unfavorable metabolite profiles: 150–300 mg/day, adjusted to labs and tolerance.
  • Men with prostate risk or aromatization-driven symptoms: 300–600 mg/day, personalized.
  • I pair DIM with omega-3s, iodine/selenium, and fiber/probiotics to support the entire estrobolome–liver–stool axis.

Rationale: By changing metabolite balance and supporting conjugation, DIM decreases receptor overstimulation and DNA-adduct risk while improving symptom stability.

Shilajit for Free Testosterone and Mitochondrial Support

Some patients—particularly young males—present with high total testosterone but low free testosterone and low vitality. Shilajit, a purified, fulvic-acid–rich resin, has randomized data showing increases in total (~31%), free (~51%), and DHT (~37%) over ~90 days at 250 mg twice daily (Pandit et al., 2016). Mechanisms likely include improved mitochondrial function, nutrient transport, and hypothalamic–pituitary–gonadal signaling.

How I use it:

  • In those seeking endogenous support without exogenous hormones, I combine shilajit with vitamin D, magnesium, zinc, B12, and iodine/selenium when indicated, then track changes in free T, SHBG, energy, and body composition.

Why this works: Enhancing mitochondrial ATP and cofactor availability raises tissue responsiveness; changes in binding dynamics can increase the bioactive fraction without pushing total testosterone to excessive levels.

Vitamin D as a Systemic Modulator: Barrier, Immunity, and Receptors

I routinely optimize vitamin D because it acts at the intersection of immunity, barrier integrity, and endocrine signaling. Observational data tie suboptimal 25(OH)D to higher risks across diseases (Bouillon et al., 2019). Mechanistically, D supports tight junction proteins, cathelicidin, and endocrine receptor sensitivity. Clinically, many patients feel “stuck” until D is restored to an optimal range; I often target 60–80 ng/mL with appropriate monitoring to avoid hypercalcemia (Holick, 2017; Rosen et al., 2012).

Integrative Chiropractic Care: The Neuroimmune–Endocrine Interface

As a chiropractor and nurse practitioner, I see daily how autonomic balance, fascial mobility, and pain modulation determine whether patients can absorb nutrients, move consistently, and sleep well—foundations for endocrine success.

  • Vagal tone and motility: Gentle spinal and cervical adjustments can influence autonomic balance, improving gut motility, secretory IgA, and anti-inflammatory vagal pathways. Patients with low vagal tone present with constipation, bloating, and poor stress resilience.
  • Fascia and diaphragm: Thoracolumbar fascial restrictions and diaphragmatic stiffness impair breathing mechanics and lymphatic flow, promoting sympathetic overdrive. Mobility restores circulation and reduces pain.
  • Pain reduction without NSAIDs: Lowering nociception decreases cortisol and protects the mucosa from NSAID-induced permeability.
  • Behavioral activation: When pain decreases, patients walk, train, and sleep—activities that increase SCFAs, improve insulin sensitivity, and stabilize mood.

These neurophysiologic effects align with published observations on autonomic modulation and musculoskeletal care (Pickar, 2002; Lehman et al., 2012) and help nutrition and endocrine strategies “stick” in daily life.

For examples of how we operationalize this, see my resources at Chiromed and my professional updates on LinkedIn.

A Phased, Clinic-Ready Protocol for Gut and Hormone Optimization

I layer care to build momentum and safety.

Phase 1: Stabilize and Build Trust (Weeks 0–4)

  • Ensure daily bowel movements; add PHGG, hydration, and magnesium as needed.
  • Start a multi-strain probiotic (Lactobacillus + Bifidobacterium).
  • Begin vitamin D3 with K2 and magnesium; consider ADK formulations.
  • Introduce walks after meals and fixed sleep schedules.
  • Provide chiropractic adjustments and diaphragmatic work to normalize autonomics and reduce pain.
  • Baseline labs: CBC, CMP, 25(OH)D, calcium, PTH, thyroid panel (TSH, free T4/T3), thyroid antibodies as needed, ferritin, B12, folate, magnesium, zinc, selenium, CRP, fasting insulin/glucose, lipid profile, estradiol, total and free testosterone, SHBG.

Phase 2: Targeted Gut Repair and Hormone Pathways (Weeks 4–12)

  • Add L-glutamine 5 g/day for barrier support when indicated.
  • Short berberine course for endotoxemia/dysbiosis; replete with probiotics.
  • Add DIM if clinical or metabolite data show proliferative pathways.
  • Start a methylated B complex to support COMT and phase II detox.
  • Maintain chiropractic care cadence for autonomic and biomechanical resilience.

Phase 3: Personalize, Monitor, and Maintain (Months 3+)

  • Reassess symptoms, bowel habits, and targeted labs; titrate to the lowest effective doses.
  • Reinforce lifestyle anchors: fiber intake, movement, sleep, and stress practices.
  • Schedule periodic tune-ups for the spine, fascia, and breath mechanics to sustain vagal tone and support recovery.

This sequencing respects physiology and behavior: patients feel better first, then commit to more significant changes—resulting in better adherence and durable outcomes.

Special Focus: PCOS and Endometriosis

PCOS

  • Emphasize insulin sensitization through fiber, postprandial walks, resistance training, and, where appropriate, berberine.
  • Reduce LPS: probiotics, polyphenols, and barrier repair to lower endotoxemia.
  • Consider inositols for ovulatory support alongside gut therapy.
  • Monitor androgenic symptoms as gut protocols progress; improvements often track with better bile acid and SCFA signaling.

Endometriosis

  • Reduce beta-glucuronidase pressure via probiotics and fiber to limit estrogen recirculation.
  • Calm neuroimmune inflammation with omega-3s, curcumin, and sleep optimization.
  • Use gentle movement and manual therapy to address pelvic floor tension and diaphragm mobility; sympathetic downshift reduces pain tone.
  • Coordinate with gynecology; gut protocols augment, not replace, indicated care.

Case Reflection: High Total Testosterone, Low Vitality

I saw an 18–19-year-old male with low mood, low energy, weight gain, and “low-T” symptoms. His total testosterone was ~900 ng/dL—clearly not low. What we found: very low vitamin D, low B12, and signs of micronutrient insufficiency. I started a robust B-complex, ADK (D3 + K2 + A), iodine paired with selenium, and magnesium. At follow-up, his mother said, “He’s a totally different person.” Energy, mood, and cognition improved, and multiple medications were discontinued. The physiology: hormones were present, but receptor signaling and cellular machinery were underpowered. Restoring micronutrients enabled the hormones to “work.”

In other young men with high total but low free testosterone, I have added shilajit and structured resistance training. Free fractions improved, and vitality followed—without pushing total testosterone into excess.

Safety, Lab Monitoring, and Personalization

  • Monitor: 25(OH)D, calcium, PTH for vitamin D repletion; thyroid panel and antibodies for iodine–selenium strategies; ferritin, B12, folate, magnesium, zinc, selenium, CRP for micronutrient and inflammatory status; sex hormones including free testosterone and SHBG.
  • Adjust doses to labs and symptoms. If vitamin D stays low despite oral dosing, assess bile flow, fat absorption, and adherence; consider supervised loading.
  • Cautions:
    • Vitamin A: avoid hypervitaminosis; use caution in pregnancy.
    • Iodine: go slowly with autonomous nodules or hyperthyroidism; collaborate with endocrinology.
    • Zinc: long-term high dosing can lower copper; keep the balance.
    • DIM and shilajit: use third-party-tested products; personalize the dose.
    • Berberine: short targeted courses; watch for GI sensitivity and drug interactions.

How Integrative Chiropractic Care Complements Endocrine and Gut Strategies

Mechanistically, chiropractic-informed care bridges biochemistry and behavior:

  • Reduces nociception and sympathetic overdrive, lowering cortisol drag on thyroid conversion and gonadal axes (Lehman et al., 2012).
  • Improves respiratory mechanics and fascial glide, supporting lymphatic flow, nutrient delivery, and waste clearance.
  • Enhances vagal tone, supporting motility, secretory IgA, and peristalsis—foundations for microbiome stability.
  • Facilitates movement prescriptions (resistance training, mobility, aerobic intervals) that reduce aromatase activity, improve insulin sensitivity, and raise androgen receptor density.

In my practice, patients combining endocrine protocols with spinal–fascial optimization report better sleep, steadier energy, more predictable lab trajectories, and lower required doses—an elegant synergy of systems biology and hands-on care. Explore our integrative approach at Chiromed and my professional notes on LinkedIn.

Why Each Technique Matters: Systems Biology Rationale

  • Fiber/PHGG: Feeds SCFA producers, tightens junctions, and supports GLP-1 signaling.
  • Probiotics: Reduce beta-glucuronidase, improve barrier integrity, and temper endotoxemia.
  • L-glutamine: Primary fuel for enterocytes; accelerates epithelial repair.
  • Berberine: Reshapes the gut microbiota, lowers LPS levels, and activates AMPK to improve insulin sensitivity.
  • DIM: Steers estrogen toward 2-hydroxylation, lowering proliferative load.
  • Methylated B vitamins: Enable COMT activity and conjugation; reduce genotoxicity of catechol estrogens.
  • Vitamin D + K2 + A + Mg: Align receptor signaling and calcium kinetics; protect vessels and bone.
  • Iodine + selenium: Support thyroid synthesis while detoxifying H2O2 to prevent autoimmune escalation.
  • Shilajit: Enhances endogenous androgens via mitochondrial and HPG-axis support.
  • Chiropractic care: Normalizes autonomic function, reduces pain, and supports movement habits that sustain microbiome and endocrine gains.

Each intervention nudges a different lever; together, they realign the system.

Clinical Observations from Practice

Across patient cohorts at my clinic, we see reproducible patterns:

  • Resolving constipation reduces PMS and “estrogen rollercoaster” symptoms within weeks.
  • Regular adjustments correlate with improved sleep and stress tolerance, enabling consistent training and meal timing that benefit the microbiome.
  • Vitamin D optimization often coincides with improved mood, less joint pain, and better responses to both gut and hormone protocols.

These observations are consistent with the mechanistic and clinical literature, reinforcing the rationale for why foundational steps deliver outsized results. For more, visit Chiromed and my LinkedIn updates.

References

Hormones: A Comprehensive Guide for Thyroid Optimization

Learn about thyroid optimization for hormones and their vital role in your health. Optimize your thyroid for improved vitality and balance.

Abstract

I wrote this educational post to share how I evaluate and treat persistent hypothyroid symptoms when traditional, TSH-centered therapy falls short. Drawing on my personal journey of living without a thyroid and more than a decade in integrated clinical practice, I explain why patients can feel hypothyroid with “normal” lab values, how the deiodinase system and reverse T3 shape symptoms, and where free T3 offers a more reliable clinical compass. I also detail why some people do better on combination T4/T3 therapy or desiccated thyroid, how nutrient cofactors like iron and selenium transform outcomes, and why lab timing and dose splitting matter. I show where integrative chiropractic care fits by improving autonomic balance, pain, sleep, and movement capacity—factors that directly influence hormone conversion and tissue response. Throughout, I integrate modern, evidence-based research and reference leading studies in endocrinology, cardiology, neurology, and rehabilitation. You will find a precise, step-by-step framework to help patients move from biochemical uncertainty to functional recovery.

The Journey Without a Thyroid and How It Shapes My Care

I practice medicine and chiropractic with a unique perspective. Many patients were required to complete thyroid removal. In the era before recombinant TSH, I experienced diagnostic withdrawal phases that pushed my TSH above 150 mIU/L. They felt the hard edge of metabolic shutdown—cold intolerance, constipation, bradypsychia (slowed thinking), and the kind of profound fatigue that flattens life.

Those deeply personal experiences transformed how I listen to and care for patients. Over the last 14 years, I have provided longitudinal care for more than 9,000 patients with thyroid-related conditions. I repeatedly see the gap between “lab-normal” and truly feeling normal in daily life. Many arrive with TSH values in range on levothyroxine yet still grapple with persistent symptoms.

In my chiropractic practice, I integrate precise spinal adjustments to optimize nervous system function and autonomic balance, thereby directly supporting endocrine regulation and helping close that gap. Patients often describe the full spectrum of thyroid imbalance: classic hypothyroid effects such as fatigue, weight gain, hair thinning, low mood or depression, brain fog, slowed cognition, dry skin, muscle weakness, constipation, cold intolerance, and exercise intolerance; as well as disruptive hyperthyroid symptoms including unintended weight loss despite increased appetite, heat intolerance, anxiety or irritability, rapid heartbeat or palpitations, diarrhea, tremors, restlessness, insomnia, and excessive sweating.

Many therapeutic journeys have reached the same conclusion: many patients need a more nuanced approach than T4 replacement alone—sometimes adding T3, correcting nutrient gaps, addressing gut-liver dysfunction, or resolving autonomic imbalance. These lived lessons anchor the whole-person framework I share here.
References for clinical updates and case observations:
ChiroMed: https://chiromed.com/
LinkedIn: https://www.linkedin.com/in/dralexjimenez/

Thyroid Physiology And Why A Normal TSH Can Mask Low Tissue Thyroid Action

To fully explain persistent symptoms, I begin with the hypothalamic-pituitary-thyroid (HPT) axis and tissue-level control:

  • The hypothalamus releases TRH, prompting the pituitary to release TSH, which signals the thyroid to make T4 and T3.
  • T3 is the bioactive hormone that binds to nuclear thyroid receptors (TRα, TRβ), upregulates mitochondrial and metabolic genes, and drives energy production.
  • Most circulating T3 is made in peripheral tissues by deiodinases. D1 and D2 convert T4 to T3, while D3 shunts T4 into reverse T3 (rT3)—an inactive isomer that competes with T3 for receptor access.

When inflammation, stress, or nutrient deficiency suppress D1 and favor D3, the result is a “low T3–high rT3” pattern. The pituitary, cushioned by local D2 activity, may “feel” replete and keep TSH within range, while muscles, brain, liver, and heart remain T3-deficient. This is how people feel hypothyroid despite a “normal” TSH.

  • Deiodinase and tissue signaling overview: (Bianco & Kim, 2018)
  • Non-thyroidal illness and low T3 physiology: (Peeters, 2017)
  • Transporter and receptor influences on intracellular signaling: (Friesema et al., 2010)

Citations:

Why Free T3 Predicts Function Better Than TSH During Treatment

In practice and research, free T3 correlates more tightly with energy, thermoregulation, cognition, and cardiometabolic outcomes than TSH when therapy is underway. While TSH is an excellent screening tool in untreated populations, it does not reliably reflect tissue thyroid status once exogenous hormone is introduced. Peripheral tissues depend on D1, which is easily downregulated by stress and illness. The pituitary’s reliance on D2 allows TSH to normalize even as free T3 remains low or rT3 rises.

  • Cardiovascular findings consistently link low T3 with worse outcomes; TSH often shows weak or no association (Dimitriadis et al., 2014; Iervasi et al., 2010).
  • In critical illness and ARDS, low T3 predicts higher mortality and delayed recovery (Wajner & Maia, 2015).

Citations:

The Reverse T3 Brake And The Conversion Ecology

I teach patients to think of reverse T3 as a physiologic brake. Under stress, inflammation, infection, caloric restriction, or high T4 loads, D3 increases and shunts T4 into rT3. Elevated rT3 effectively blocks T3’s action by competing for receptor and transport access.

  • Symptoms of high rT3/low T3: fatigue, cold intolerance, constipation, dry skin, sluggish thinking, reduced exercise tolerance.
  • Clinical reasoning: Adding more T4 in a high rT3 state often worsens the problem by feeding the brake. We must address stressors, reduce inflammation, optimize cofactors, and, when indicated, add physiologic T3.

Mechanistic reviews:

Levothyroxine Alone: When The Assumptions Fail

The traditional assumption was that T4-only therapy would convert adequately to T3 and fully resolve symptoms. Many patients do improve on levothyroxine. Yet a meaningful proportion remain symptomatic because of impaired conversion or high rT3.

  • Genetic polymorphisms (e.g., DIO2 Thr92Ala) and inflammatory states alter T3 production and action (Panicker et al., 2009).
  • Caloric restriction, illness, and iron deficiency shift deiodinase activity away from T3 (Stott et al., 2019).

A physiologic alternative is to use combination therapy (T4 + T3) or desiccated thyroid (DTE) for select patients with persistent symptoms, carefully titrated and monitored for safety.
Citations:

The Testosterone Connection And Metabolic Synergy

Thyroid hormones and androgens co-regulate metabolic rate, muscle protein synthesis, and mitochondrial efficiency:
Hypothyroidism can downregulate androgen receptors; low testosterone reduces muscle mass and worsens fatigue (Kelly & Jones, 2015).

  • Thyroid hormones increase SHBG, thereby altering the free fractions of testosterone and estradiol (Davis & Wahlin-Jacobsen, 2015).
  • Visceral adiposity increases aromatase activity, further lowering free testosterone. Optimizing thyroid action reduces central fat and indirectly improves androgen balance.

Citations:

An Evidence-Guided Evaluation Framework I Use In Clinic

To identify root causes of persistent symptoms, I apply a structured model:

  • Comprehensive thyroid panel and dynamics
    • TSH, free T4, free T3, and reverse T3 to map supply, conversion, and braking.
    • Thyroid antibodies (TPOAb, TgAb) for autoimmunity surveillance.
    • Consistent lab timing relative to dosing.
  • Nutrient and hematologic status
    • Ferritin, iron indices, selenium, zinc, vitamin D, vitamin A, B12; iodine assessment when indicated and carefully monitored.
    • Rationale: cofactors enable hormone synthesis and conversion (Zimmermann & Köhrle, 2002).
  • Inflammation and metabolic health
    • hsCRP, fasting insulin, HOMA-IR, lipids, liver enzymes; body composition for lean mass and visceral fat.
  • Gut-liver axis
    • Screen dysbiosis/SIBO symptoms, celiac markers, NAFLD risk, bile flow, and constipation patterns (Docimo et al., 2021).
  • Autonomic nervous system and stress load
    • HRV, orthostatic vitals, sleep quality, perceived stress.
  • Sex hormones and adrenal rhythm (as indicated)
    • Total and free testosterone, SHBG, estradiol, LH/FSH; DHEA-S; consider cortisol profiles when warranted.

Citations:

Precision Dosing: Why Lab Timing And Dose Splits Matter

When I incorporate T3 (liothyronine) or use desiccated thyroid, I standardize lab draws at five to six hours after the morning dose and split doses to avoid peaks:

  • Pharmacokinetics: Oral T3 peaks about 1–2 hours after ingestion and declines over the next several hours. Drawing at 5–6 hours captures a mid-curve snapshot that is comparable across visits (Ross, 2022; Jonklaas et al., 2019).
  • Dose splitting: I typically use BID or TID schedules (e.g., 6:00 a.m., 12:00 p.m., 6:00 p.m.) to maintain steady intracellular T3 for mitochondrial throughput, cognitive function, and thermoregulation. This dramatically reduces palpitations and anxiety tied to early peaks.
  • Wearables: I ask patients to track heart rate and sleep. Post-dose pulse spikes confirm kinetic peaks and guide redistribution.

Citations:

Combination Therapy And Desiccated Thyroid: How I Use Them And Why

I consider combination T4/T3 or desiccated thyroid extract (DTE) for patients with persistent symptoms and a lab pattern of low free T3 and/or elevated rT3:

  • Start low and titrate slowly
    • Introduce small, divided T3 doses to avoid peak-related side effects.
    • Maintain a baseline T4 level for substrate, while ensuring receptor activation by T3.
  • DTE practicals
    • Typical starting range: 1–1.5 grains (60–90 mg) daily, individualized to prior T4 dose and sensitivity.
    • Transition approach: a two-week half-and-half overlap (half prior T4 dose plus half new DTE dose) to avoid T3-naïve jitters.
    • Limit large single doses; distribute across the day if a higher total daily dose is needed.
  • Monitoring
    • Symptoms, free T3, free T4, and safety markers (heart rate, blood pressure).
    • Long-term: bone density surveillance when higher T3 exposures are used in specific populations.

Evidence-based and patient preference data:

Nutrient Therapy That Changes Outcomes: The Thyroid

The thyroid hormone is a signal, but the body needs substrates and cofactors to translate that signal into action. I routinely assess and treat:

  • Iron repletion when ferritin is low (often targeting >50–70 ng/mL for thyroid optimization)
    • Iron supports thyroid peroxidase and deiodinase function; low ferritin levels blunt T4-to-T3 conversion and can mimic hypothyroid symptoms.
  • Selenium (100–200 mcg/day from diet/supplement)
    • Supports deiodinase activity and antioxidant defense; may modestly reduce TPO antibodies (Winther et al., 2020).
  • Zinc, vitamin D, vitamin A, and B12
    • Zinc facilitates receptor function; vitamin D modulates immune tone and muscle; vitamin A supports epithelial and receptor dynamics.
  • Protein sufficiency (often 1.2–1.6 g/kg/day)
    • Supports thyroid transport proteins, hepatic conversion, and muscle mass.

Citations:

Integrative Chiropractic Care: Autonomic Regulation, Pain Reduction, And Metabolic Performance

As a DC and APRN, I see daily how neuromusculoskeletal health and the autonomic nervous system shape endocrine outcomes. Integrative chiropractic care fits into thyroid optimization by:

  • Autonomic regulation
    • Gentle spinal manipulation and soft-tissue techniques reduce nociceptive input and sympathetic overdrive, improving vagal tone and HRV. Lower stress signaling supports D1 activity, reduces rT3, and improves sleep quality.
  • Pain reduction
    • By reducing chronic pain, we lower inflammatory cytokines (e.g., IL-6, TNF-α) that suppress deiodinases and disrupt sleep, thereby enabling better hormone conversion and tissue responses.
  • Movement-based care
    • Structured resistance training and aerobic intervals, guided by movement assessment, improve insulin sensitivity, GLUT-4 translocation, and mitochondrial density, amplifying T3’s metabolic impact.
  • Breath and posture
    • Thoracic mobility and diaphragmatic breathing enhance oxygenation, vagal tone, and sleep—key supports for endocrine stability.


Clinical observations:
In my practice at ChiroMed, patients who pair optimized thyroid therapy with chiropractic autonomic optimization, mobility work, and progressive strength programming recover faster, maintain better energy, and sustain fat loss more reliably. See clinical reflections and case pearls:

Metabolic Rehabilitation: Building A Physiology That Welcomes T3

Thyroid optimization alone rarely solves modern metabolic challenges. I employ a pragmatic blueprint:

  • Build muscle first
    • Two or more weekly full-body resistance training sessions with progressive overload. More muscle equals a higher basal metabolic rate and better glucose disposal.
  • Walk the thermostat
    • 7,000–10,000+ daily steps, with postprandial 10–15-minute brisk walks, to blunt glucose excursions and lower inflammation.
  • Prioritize sleep and rhythm.m
    • Stable sleep-wake times, morning light exposure, and evening light reduction improve HPT-axis signaling and insulin sensitivity.
  • Protein-forward nutrition
    • 25–40 g protein per meal; fiber-rich plants and healthy fats; minimize ultra-processed foods.
  • Micronutrient sufficiency
    • Emphasize seafood (selenium, iodine), lean meats (iron, zinc, B12), eggs (vitamin A), and leafy greens (folate, magnesium).
  • Stress modulation
    • Breathing practices, HRV-guided recovery, and time in nature lower cortisol and rT3.
  • Manual and chiropractic care
    • Identify and correct joint restrictions and postural dysfunctions that limit training and raise sympathetic tone.

Epidemiologic context: U.S. obesity prevalence continues to rise, underscoring the need to embed thyroid care within a broader metabolic strategy (CDC, 2023).
Citation:

Thyroid Dysfunction-Video

Safety And Monitoring: Cardiac And Bone Health With T3

I titrate T3 conservatively and monitor:

  • Cardiac status (resting pulse, symptoms; ECG as indicated in arrhythmia-prone patients).
  • Bone health (ensure adequate calcium and vitamin D, prioritize resistance training, and follow DEXA for at-risk individuals).
  • Symptoms and function (energy, thermoregulation, bowel rhythm, cognition, sleep).
  • Free T3/Free T4, with TSH interpreted cautiously under T3-containing regimens.

A key clinical distinction: TSH suppression on therapy is not the same as endogenous hyperthyroidism. In thyroid cancer cohorts, carefully managed TSH suppression does not universally increase atrial fibrillation or osteoporosis risk when free hormones and clinical markers are appropriately monitored. We individualize targets rather than relying on a single lab threshold.
Reviews:

Standardizing Testing: Reducing Noise And Improving Decisions

The most powerful lever in precision thyroid care is standardization:

  • Fix dosing times (e.g., 6:00 a.m., 12:00 p.m., 6:00 p.m.).
  • Lock blood draws at five to six hours after the morning dose.
  • If patients arrive outside the window, reschedule to keep results comparable.
  • Use simple EMR notes to track outcomes: “Free T3 improved; patient reports better focus and energy; no adverse effects at standard draw; pulse stable.”

This rigor transforms guesswork into reliable, reproducible decisions.
Citations:

Case Patterns From Practice: How The Physiology Plays Out

The “stuck but strict” patient

  • A woman on levothyroxine with normal TSH but persistent fatigue and weight gain. Ferritin was 18 ng/mL; vitamin D was 22 ng/mL; rT3 was elevated. After iron and vitamin D repletion, post-meal walking, and low-dose T3 add-on, energy rose within weeks. Resistance training resulted in a 6% relative reduction in body fat over four months; we later tapered levothyroxine as conversion normalized.

The “pain-metabolism loop.”

  • A man with low back pain avoided exercise and gained weight while on stable thyroid replacement therapy. Integrative chiropractic care reduced pain and improved mobility. We added a graded strength plan and sleep coaching; HRV improved. With modest T3 addition, he reported clearer thinking and greater stamina.

The”testosterone trap.”

  • A man sought testosterone for fatigue and low libido. Evaluation revealed low-normal free T3, elevated rT3, high stress, and poor sleep. We prioritized thyroid optimization, sleep, and resistance training. Free testosterone improved without exogenous testosterone; symptoms resolved.

Clinical notes and similar cases:

Practical Steps For Patients And Clinicians

Patients

  • Ask for a comprehensive thyroid panel: TSH, free T4, free T3; consider reverse T3 if symptoms persist.
  • Check ferritin, selenium, zinc, vitamin D, and B12; discuss iodine only with clinical guidance.
  • Standardize dosing times and lab draw timing; split doses if needed to reduce peaks.
  • Build muscle, walk after meals, and protect sleep; track pulse and sleep with wearables if possible.
  • Consider integrative chiropractic care to improve pain, autonomic balance, and movement capacity.

Clinicians

  • Treat the person, not just the lab. If symptoms persist with “normal” TSH, investigate conversion ecology, cofactors, and comorbidities.
  • Consider cautious T4/T3 combination or DTE trials with standardized monitoring and safety tracking.
  • Pair endocrine therapy with nutrition, sleep, stress care, and chiropractic/rehab partners.
  • Reassess as inflammation, body composition, and fitness improve; the right dose today may be excessive in six months.

Closing Perspective: Aligning Therapy With Physiology

Living without a thyroid taught me respect for the complexity of endocrine physiology and the limits of single-number thinking. Care improves when we align therapy with how the body actually works: ensure adequate hormone supply; correct cofactor deficiencies; calm the autonomic nervous system; build muscle; and remove friction points such as pain, inflammation, and poor sleep. When we combine personalized thyroid replacement, targeted nutrient therapy, and integrative chiropractic care within a metabolic rehabilitation framework, patients stop treading water and begin moving forward.

References

SEO tags: thyroid optimization, free T3, reverse T3, deiodinase enzymes, levothyroxine, liothyronine, T4 T3 combination therapy, desiccated thyroid, ferritin and thyroid, selenium thyroid, autonomic balance, integrative chiropractic care, HRV thyroid, lab timing thyroid, split dosing T3, Hashimoto’s treatment, metabolic rehabilitation, resistance training hypothyroidism, gut liver thyroid axis, suppressed TSH safety, Dr. Alexander Jimenez,

Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Hormone Balance, Iron Health, and Contraceptive Care

Abstract

As a clinician blending chiropractic, functional medicine, and advanced nursing practice, I see how hormone physiology, micronutrients, and systems biology converge to shape health, recovery, and resilience. In this educational post, I walk you through practical, evidence-informed strategies for evaluating iron deficiency and ferritin; interpreting cortisol and thyroid dynamics; selecting and titrating progesterone, estrogen, and testosterone in complex scenarios (PCOS, IUD selection, male fertility and TRT rebound, TIA and stroke risk considerations, endometriosis, and menopause); and understanding the nuanced oncology context around DCIS and hormone receptors. I also explain how integrative chiropractic care fits into these plans by balancing the nervous and hormone systems, improving body functions, and supporting health through hands-on therapy, exercise, sleep, and diet. Throughout, I present current literature from leading researchers and add real-world observations from my practice (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST) to help you translate physiology into precise, patient-centered care.

Foundations Of Identity In Care Planning And Clinical Context

  • Why this matters: Many patients navigate multiple identities—athlete and parent, caregiver and executive, patient and advocate. Clinically, multiple identities often map onto competing physiological stresses: sleep compression, high allostatic load, and variable patterns of nutrition and movement. Recognizing these factors is the first step in aligning care with lived realities.
  • Integrative chiropractic fit: In my clinic, identity-informed care plans build adherence. When I address spine and fascial mechanics and autonomic balance with targeted manual therapy, patients experience immediate relief that reinforces engagement with longer-term hormonal and nutritional strategies. Clinically, I see better follow-through on lab timing, supplement dosing, and structured movement when the body feels aligned and capable.

Iron Physiology, Ferritin, And Root-Cause Mapping

Understanding iron requires separating storage, transport, and utilization:

  • Key biomarkers:
    • Serum ferritin: a proxy for iron stores but an acute-phase reactant—elevates with inflammation (hepcidin-mediated sequestration).
    • Serum iron and transferrin/TIBC: reflect circulating iron and binding capacity.
    • Transferrin saturation (%): often the most useful single index with ferritin.
    • Reticulocyte hemoglobin (CHr) and soluble transferrin receptor (sTfR): help distinguish true deficiency from anemia of inflammation.

Physiology in brief:

  • The liver peptide hepcidin governs iron absorption and release from macrophages. Inflammation increases hepcidin, lowering absorption and locking iron in stores—low iron availability with normal/high ferritin.
  • True iron deficiency presents with low ferritin, low iron, high TIBC, and low transferrin saturation. Anemia of chronic inflammation shows low iron, low/normal TIBC, and normal/high ferritin.

Why patients stay iron-deficient:

  • Decreased intake or high phytate/polyphenol diets limit absorption.
  • Malabsorption: hypochlorhydria, celiac spectrum, SIBO, gastric bypass.
  • Losses: heavy menses, GI blood loss, frequent phlebotomy, and endurance training.
  • Special populations: neonates can experience early postnatal physiologic shifts; in adults, postpartum, post-surgery, and endurance athletes require tailored screening.

Clinical approach I use:

  • Map the cause: hydration status, GI absorption, occult bleeding (including fecal immunochemical testing), menstrual history, PPI use, celiac panel if indicated, and inflammatory markers (CRP, ESR).
  • Replace iron physiologically: I favor alternate-day oral iron to align with hepcidin’s diurnal rhythm and reduce GI side effects, supported by recent randomized trials showing improved absorption with every-other-day dosing (Stoffel et al., 2017). Using ferrous bisglycinate or heme iron polypeptide can enhance tolerance.
  • Repletion targets: Bring ferritin to symptom-relief thresholds (often 50–100 ng/mL for fatigue and hair loss), then sustain. Monitor hemoglobin, ferritin, and transferrin saturation every 8–12 weeks during repletion.

Integrative chiropractic fit:

  • Manual therapies that improve thoracic mobility and diaphragmatic excursion enhance vagal tone and GI perfusion, supporting absorption. Coaching on timing iron away from calcium and with vitamin C-rich foods further increases uptake. I often see faster symptom improvement when we combine postural breathing retraining and gentle aerobic conditioning with iron repletion.

Hormonal IUDs, Progestin Families, And Thrombotic Risk

Not all progestins are the same. Families differ in androgenicity and thrombotic risk:

  • Levonorgestrel (Mirena and similar): primarily a local uterine effect with low systemic levels; robust evidence supports low VTE risk compared with systemic progestins (ACOG, 2022).
  • Norethindrone: different side-effect profile and hepatic metabolism from progesterone; systemic exposure carries VTE risk similar to combined oral contraceptives when used in combination with estrogen.
  • Biologic progesterone (micronized) differs from synthetic progestins in receptor activity and in metabolites (e.g., allopregnanolone), which influence mood and sedation.

Why are Levonorgestrel IUDs often well tolerated?

  • The local endometrial action results in reduced systemic exposure, decreased bleeding, and endometrial protection, with a favorable safety profile. This is one reason neurosurgical and periprocedural contexts prefer local or targeted effects when feasible—namely, to reduce systemic adverse events.

Integrative chiropractic fit:

  • Pelvic floor integration matters. I routinely coordinate pelvic floor assessment and diaphragmatic mechanics with IUD choice. Improved lumbopelvic control and reduced sympathetic arousal can decrease cramping and improve IUD tolerance.

Progesterone Strategy In Sensitive Patients And PCOS Contexts

Clinical problem: Some patients with PCOS or HPA dysregulation report mood lability with oral progesterone.

Physiology:

  • Oral micronized progesterone converts to allopregnanolone, a positive allosteric modulator of GABA-A receptors. In most, this is anxiolytic; in a sensitive minority, neurosteroid fluctuations can provoke dysphoria.
  • Sublingual and transdermal routes bypass some first-pass metabolism, altering metabolite profiles and CNS effects.

My approach:

  • Start with a low-dose oral micronized progesterone (e.g., 100 mg qHS) to promote sleep and provide endometrial protection. If not tolerated:
    • Switch to a sublingual troche at half the equivalent oral dose (sublingual tends to achieve higher bioavailability; clinically, 100 mg sublingual can approximate 200 mg oral).
    • Quartering a 200 mg troche yields ~50 mg sublingual aliquots for fine titration.
  • Why this works: By modulating route and dose, we can smooth neurosteroid peaks, reduce daytime sedation, and maintain endometrial safety when used with estrogen.
  • For PCOS on androgen therapy: Balance is critical. A small androgen signal can be synergistic for mood, energy, and libido, but carefully calibrate it with estrogen and progesterone to avoid endometrial hyperplasia, acne, or dyslipidemia. Track SHBG, lipids, and insulin resistance.

Integrative chiropractic fit:

  • Autonomic stabilization through cervical-thoracic manipulation and breathing retraining reduces adrenergic drive that often amplifies progesterone sensitivity. When we address sleep quality and nocturnal bruxism with TMJ and cervical work, I see smoother adaptation to progesterone in practice.

Cortisol Testing: Salivary Profiles Versus Serum

Why measure multiple points:

  • Cortisol follows a diurnal curve: a peak within 30–45 minutes after waking (CAR) and a gradual decline throughout the day. A single AM serum cortisol measurement may miss dysregulated patterns.
  • A 4–5-point salivary cortisol series captures CAR, midday, afternoon, and evening levels—useful for sleep disturbances, burnout, and suspected HPA axis alterations (O’Connor et al., 2021).

When I choose each:

  • For pattern analysis and sleep complaints: multi-point salivary cortisol.
  • For adrenal insufficiency screening or acute illness: AM serum cortisol ± ACTH stimulation.

Integrative chiropractic fit:

  • Chiropractic care and breath-led movement can normalize autonomic balance, often flattening hyper-adrenergic spikes that correlate with evening cortisol elevations. I pair care with light-in-the-morning, dim-in-the-evening routines to reinforce circadian rhythms.

Male Fertility, Clomiphene, And TRT Rebound

In men in their 20s–30s with low testosterone who want fertility:

  • I avoid long-term estrogen receptor blockade. Short courses of clomiphene citrate (3–6 months) can increase LH/FSH levels, thereby increasing endogenous testosterone and sperm counts (Helo et al., 2017). It is not for indefinite use due to visual and mood risks and potential lipid changes.
  • Off peptides/TRT: I use timed clomiphene or enclomiphene to accelerate spermatogenesis while lifestyle and nutrition restore HPG axis tone.
  • Foundational first: For younger men, I prioritize diet quality, sleep, resistance training, weight normalization, and correcting micronutrient levels (vitamin D, B-complex, zinc, magnesium). I frequently see total testosterone rise from low 300s into 700–800 ng/dL over 6–9 months with lifestyle adherence.

Integrative chiropractic fit:

  • Restoring thoracic mobility and rib mechanics improves breathing efficiency and training capacity; correcting lumbopelvic mechanics reduces systemic inflammation from overuse. The autonomic shift toward parasympathetic tone deepens sleep, which is crucial for nocturnal gonadal hormone secretion.

DCIS, Hormone Receptors, And Personalized Risk-Benefit

Terminology and nuance:

  • Ductal carcinoma in situ (DCIS) is a noninvasive neoplastic process confined to the ducts. While often called “stage 0 breast cancer,” it lacks stromal invasion; management varies widely.
  • Receptor positivity (ER, PR, AR) indicates ligand-responsive pathways. Receptors are normal cellular features; their presence does not inherently mandate systemic suppression in all contexts.

Standard-of-care realities:

  • Many oncology pathways default to anti-estrogen strategies (e.g., tamoxifen) in receptor-positive lesions. My stance: align with oncology for invasive disease or recent treatment, but individualize for remote history or post-mastectomy scenarios, considering symptom burden and quality-of-life outcomes (Early Breast Cancer Trialists’ Collaborative Group, 2011; Cuzick et al., 2011).

Clinical reasoning:

  • In a patient decades post-bilateral mastectomy with no residual breast tissue, the theoretical tissue-specific risk is different from that of a patient 6 months post-lumpectomy still on adjuvant therapy. I weigh the systemic benefits of estrogen (bone, vasomotor stability, cognition, urogenital health) against realistic tissue risks, use shared decision-making, and document this via informed consent.

Integrative chiropractic fit:

  • Many of these patients struggle with pain, sleep disruption, and deconditioning. Postural restoration, scar mobility work, and gentle strengthening reduce sympathetic load, allowing lower-dose hormone regimens to achieve symptom control.

TIA, Stroke Risk, And Sex Hormones

Historical concern has linked estrogen to stroke risk, particularly in oral forms and in older trials with higher doses started late after menopause. The modern view:

  • Route matters: Transdermal estradiol has a more favorable thrombotic profile than oral estradiol because it bypasses first-pass hepatic effects on clotting factors (Canonico et al., 2016).
  • Testosterone does not require routine discontinuation after TIA in carefully selected women and men; the focus is on global vascular risk management (blood pressure, glycemic load, sleep apnea, hematocrit monitoring in men on TRT).
  • In patients who received pellet therapy near a TIA event, I evaluate vascular risks comprehensively. Anecdotally and mechanistically, sustained androgen levels do not necessarily precipitate cerebrovascular events; confounding factors (dehydration, arrhythmia, migraine with aura, hypercoagulable states) must be assessed.

Why integrative care helps:

  • Cervical and upper thoracic biomechanical dysfunction can aggravate headaches and sympathetic tone. By improving cervical proprioception, rib mechanics, and breathing patterns, I observe reduced migraine frequency and better control of blood pressure variability, which complements hormone prudence.

Immediate-Release Versus Extended-Release In Symptom Relief

In my practice, I often choose immediate-release formulations when seeking neurosensory benefits (e.g., anxiolysis, sleep initiation) from agents with CNS effects because:

  • Faster onset can more directly target symptom windows (e.g., bedtime).
  • It allows finer titration and identification of dose-response relationships.

When I choose extended-release:

  • For hormones or agents where steady state is crucial to avoid peaks/valleys, or when side effects are dose-peak-related. Personalization is key.

Endometriosis And Menopause: Progesterone Essentials

Key principles:

  • In menopausal women with a history of endometriosis on estrogen therapy, I favor co-prescribing progesterone even without a uterus. Rationale: ectopic endometrial implants may persist extrauterine and remain hormonally responsive. Progesterone has anti-proliferative effects on endometrial tissue and may reduce the risk of malignant transformation (Vercellini et al., 2014).

Testosterone and endometriosis:

  • Testosterone generally has neutral direct effects on endometriotic lesions; symptom modulation is more indirect (energy, libido, mood). I monitor acne, hair growth, and lipids.

Integrative chiropractic fit:

  • Pelvic and lumbosacral mechanics impact pelvic congestion and pain. Coordinated pelvic floor therapy, sacroiliac mobilization, and graded movement often reduce pain and allow lower estrogen doses with better function.

Thyroid Physiology: T4, Reverse T3, And Desiccated Thyroid

Why do some patients struggle with isolated levothyroxine?

  • T4 to T3 conversion is context-dependent: inflammation (IL-6), chronic stress (cortisol), and caloric restriction increase deiodinase 3, generating reverse T3 as a protective brake.
  • Bolus T4 dosing can, in sensitive patients, drive higher reverse T3 and leave tissues relatively hypothyroid despite normal TSH and free T4.

When I consider combination therapy:

  • If free T3 is low-normal with symptoms and reverse T3 is elevated, a trial of T3 addition or desiccated thyroid can be considered, monitoring HR, BP, and symptoms.
  • Desiccated thyroid includes T1/T2 in addition to T4/T3; while evidence is mixed, some patients report improved well-being (Hoang et al., 2013). The physiologic appeal is a more native ratio of iodothyronines.

Dosing logic:

  • Keep total T3 exposure rational (avoid overtreatment). Many patients do well at conservative desiccated doses (e.g., 60–120 mg with split dosing) or modest liothyronine add-on.
  • If reverse T3 is persistently high, look upstream: inflammation, gut dysbiosis, iron deficiency, sleep apnea, and medications. Raising the dose alone rarely fixes a conversion problem.

Integrative chiropractic fit:

  • By improving sleep quality and decreasing pain, we reduce cortisol and catecholamine tone that can impair peripheral conversion. I frequently pair thyroid adjustments with gut-directed nutrition, iron repletion, and aerobic conditioning to normalize deiodinase activity.

Estriol, Estradiol, And Skin Or Urogenital Targets

  • Estriol (E3) is a weaker estrogen with higher affinity for ER-beta, associated with urothelial and skin benefits and a theoretical reduced proliferative risk profile (Labrie et al., 2017).
  • On its own, estriol is often too weak for vasomotor symptoms; patients may continue to have hot flashes with estriol pellets or low-dose creams.
  • Bi-est combinations (estriol + estradiol) can increase serum estradiol; monitor for bleeding. For vulvovaginal atrophy, low-dose local estradiol or estriol is typically effective with minimal systemic absorption.

Integrative chiropractic fit:

  • Postural improvement, hip mobility, and pelvic floor coordination augment local tissue perfusion and sexual function. Patients often need lower topical doses when musculoskeletal contributors are addressed.

TRT In Men: Hematocrit, Estradiol, And Practical Monitoring

For men on testosterone injections who feel great but develop high hematocrit:

  • Tactics include dose and interval adjustments, switching to transdermal forms, therapeutic phlebotomy if indicated, and addressing sleep apnea, hydration, and iron stores.
  • I monitor hematocrit, estradiol, SHBG, PSA, lipids, and blood pressure. Aromatization to estradiol can be beneficial for bone and mood; I avoid reflexive overuse of aromatase inhibitors and instead optimize dose and lifestyle.

Integrative chiropractic fit:

  • Correcting thoracic outlet and rib mechanics can support breathing and reduce sleep apnea severity alongside weight loss—a key driver of safer TRT hematology.

Gut-First When Thyroid Therapy “Should Work” But Doesn’t

When free T3 is approaching the target (e.g., 4.0+ pg/mL), yet patients still feel unwell:

  • I reassess gut health: dysbiosis, SIBO, post-viral inflammation, food sensitivities. The gut-liver axis modulates thyroid hormone metabolism and immune cross-talk, particularly in Hashimoto’s.
  • I commonly see symptom breakthroughs after:
    • Eliminating trigger foods (gluten in celiac spectrum; individualized otherwise),
    • Repleting selenium, zinc, iron, vitamin D, B12, and magnesium, and
    • Restoring sleep and movement rhythm.

Integrative chiropractic fit:

  • Vagal stimulation through breathing and thoracic mobilization, coupled with graded walking and core stability, improves motility and lowers systemic inflammatory tone.

Clinical Vignettes And Observations From Practice

  • Ferritin plateaus despite oral iron: With alternating-day dosing with vitamin C, stopping concurrent calcium, checking for H. pylori and celiac markers, and adding diaphragmatic breathing drills for reflux, patients often see ferritin rise to 60–100 ng/mL within 12–16 weeks. Combining manual therapy to reduce costal margin restriction improved tolerance of iron and reduced GERD complaints in my clinic.
  • Progesterone intolerance in perimenopause: Switching from 200 mg oral nightly to 50–100 mg sublingual in divided evening doses, plus cervical release and sleep hygiene, stabilized mood and sleep within two cycles for most sensitive patients.
  • Young male with low T and fatigue: A 9-month plan emphasizing whole-food nutrition, vitamin D repletion to 40–60 ng/mL, magnesium glycinate at night, and progressive resistance training raised total testosterone from 320 ng/dL to 760 ng/dL without medications. Thoracic mobility and hip hinge training improved recovery and adherence.
  • Post-DCIS symptom burden: In a patient more than a decade post-bilateral mastectomy with severe vasomotor symptoms, a carefully titrated transdermal estradiol patch with nightly progesterone, plus scapular mobility and postural rehabilitation, improved sleep and cognition. Shared decision-making and documented informed consent were essential.

Why Integrative Chiropractic Care Amplifies Endocrine Therapies

  • Autonomic regulation: Pain and joint dysfunction heighten sympathetic tone, disrupting sleep, glucose metabolism, and thyroid hormone conversion. Manual therapy, spinal mobilization, and breathing retraining shift HRV toward parasympathetic balance, creating a biological environment in which hormones function as intended.
  • Movement economy: Efficient biomechanics reduce inflammatory signaling from microtrauma and improve insulin sensitivity, crucial for PCOS, TRT safety, and thyroid action.
  • Adherence and feedback loops: Rapid musculoskeletal relief builds trust and momentum, making it easier to sustain nutrition, sleep, and medication regimens. Clinically, I consistently see greater lab improvements when patients are engaged in both structured movement and manual care.

Practical Protocol Checklists

Iron and ferritin

  • Assess ferritin, iron, TIBC, transferrin saturation, CRP, ESR, CBC, retic Hb.
  • Identify cause: menses, GI loss, malabsorption, diet, PPI use.
  • Replace with alternate-day dosing; recheck at 8–12 weeks.
  • Add diaphragmatic breathing and gentle conditioning.

Progesterone strategies

  • Start 100–200 mg oral micronized qHS; if intolerant, consider 50–100 mg sublingual divided.
  • For estrogen users, ensure endometrial protection.
  • In the history of endometriosis, there is a continued use of estrogen and progesterone even post-hysterectomy.

Cortisol evaluation

  • Use 4–5-point salivary cortisol to assess diurnal rhythm; AM serum for insufficiency screening.
  • Implement light therapy, sleep hygiene, and autonomic-balancing manual care.

Male fertility/TRT

  • For fertility: short-course clomiphene 3–6 months with lifestyle-based.
  • On TRT: monitor hematocrit, estradiol, SHBG, PSA, BP; address sleep apnea.
  • Optimize resistance training and recovery.

Thyroid optimization

  • If reverse T3 is high and symptoms persist, investigate inflammation and gut.
  • Consider T3 add-on or desiccated thyroid with careful monitoring.
  • Support with selenium, zinc, iron, and vitamin D; improve sleep and stress load.

Estriol/estradiol

  • Use local estradiol or estriol for urogenital symptoms; monitor if combining with estradiol systemically.
  • Expect estriol alone to be too weak for hot flashes.

Closing Perspective

Modern endocrine care thrives at the intersection of precise physiology and whole-person mechanics. When we calibrate hormones thoughtfully, correct nutrient deficits, and restore movement and autonomic balance, patients experience durable improvements in energy, cognition, metabolism, and quality of life. Integrative chiropractic care is not an add-on; it is a force multiplier—aligning the nervous system and musculoskeletal frame to receive and respond to biochemical therapies. My day-to-day observations mirror the literature: when we treat the individual and the system, outcomes follow.

References

A Modern, Integrative Approach to Thyroid Optimization

A Modern, Integrative Approach to Thyroid Optimization

A Modern, Integrative Approach to Thyroid Optimization

Abstract

For decades, the standard approach to treating hypothyroidism has centered on a single lab value—Thyroid-Stimulating Hormone (TSH)—and a single medication, synthetic T4 (levothyroxine). However, an increasing body of evidence and extensive clinical observations indicate that this approach is fundamentally flawed for a significant proportion of patients. Many individuals on T4-only therapy continue to suffer from debilitating hypothyroid symptoms like fatigue, weight gain, hair loss, and depression, despite their TSH levels appearing “normal.” This educational post will explore the intricate physiology of thyroid hormone, explaining why T4 is a prohormone and why active T3 is the key to metabolic health. We will deconstruct the limitations of TSH testing, explore the critical process of T4-to-T3 conversion, and introduce the problematic role of Reverse T3. Drawing from the latest evidence-based research and my own clinical experience, I will outline a more comprehensive, patient-centered approach to diagnosing and managing thyroid dysfunction. We will discuss the vital importance of Free T3 (FT3), the shortcomings of standard lab ranges, and the clinical benefits of combination therapy, including Natural Desiccated Thyroid (NDT). Furthermore, I will explain the critical, yet often overlooked, role of iodine and how integrative chiropractic care forms a foundational part of treatment by optimizing nervous system function and supporting the body’s innate ability to heal.

Rethinking Thyroid Care: Moving Beyond Outdated Protocols

As a practitioner with credentials spanning chiropractic, advanced practice nursing, and functional medicine (DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST), I have dedicated my career to challenging long-held conventions in healthcare to identify what truly works for patients. Today, I want to guide you on a journey into the world of the thyroid, and in doing so, I may need to unravel some of what you’ve come to understand from conventional medical training. My goal is not to create a new, complicated system but to return to a more fundamental, physiological truth. My goal is to assist individuals in returning to a lifestyle that aligns with the natural and optimal design of our bodies.

For over a decade, I’ve focused on this physiological approach, and the feedback from patients at my clinic has been overwhelmingly positive. They feel better, their symptoms resolve, and their lives are transformed. This isn’t based on a fad; it’s grounded in pure physiology. When we appreciate and work with the body’s intricate systems instead of against them, we see profound clinical success. This is particularly true when it comes to the thyroid.

Thyroid Hormone: Your Body’s Metabolic Engine

The thyroid hormone is the master regulator of your metabolism. It dictates the speed of nearly every cellular process in your body. Think of it as the engine’s pace car. It controls:

  • Energy Production: Your overall rate of energy expenditure.
  • Temperature Regulation: Why you might feel cold when others are comfortable.
  • Growth Rates: How fast your hair and nails grow.
  • Gastrointestinal Motility: The speed of your digestive system influences constipation or diarrhea.
  • Cellular Health: Research has even linked low levels of the active thyroid hormone T3 to an increased risk of certain cancers.

The Synthroid Paradox: Normal Labs, Persistent Symptoms

The most widely prescribed thyroid medication in history is levothyroxine, with Synthroid being the most recognizable brand name. Yet, in my clinical practice, I see a daily parade of patients who are taking it and are still miserable. I recently saw a patient who had been on a stable dose of Synthroid for years. Her endocrinologist told her that her labs were perfect, with a TSH of 1.5. Yet, her chart told a different story.

  • Chief Complaint: Fatigue. She was exhausted.
  • Clinical Signs: She was wearing a thick jacket in my office… in the middle of a Texas July.
  • Other Symptoms: She was constipated, and her hair was falling out in clumps.

Her labs may have looked “normal,” but she was a walking textbook of hypothyroid symptoms. If her thyroid replacement were truly working, she would not have these symptoms. Clearly, something was not right.

This scenario is the direct result of a historical confluence of events. Synthroid was approved around 1960 based on two simple criteria: it normalized the TSH, and it didn’t cause immediate harm. It was never studied for its ability to resolve the clinical symptoms of hypothyroidism. Around the same time, the ultra-sensitive TSH assay was developed and quickly became the “gold standard” lab test.

Medical schools and residency programs immediately adopted this new paradigm: Diagnose with TSH, treat with Synthroid, and monitor with TSH. This simplistic loop became dogma. The patient’s well-being became secondary to achieving a “normal” lab number. This is a fundamental flaw in modern endocrinology, and it’s leaving millions of patients to suffer unnecessarily.

Redefining Hypothyroidism: A Deeper Look at T3 and T4

To fix this problem, we must first redefine it. The conventional definition of hypothyroidism is based on a lab test. A functional and more accurate definition focuses on the body’s physiological state.

  • Type 1 Hypothyroidism: This is a production problem. The thyroid gland itself is not producing enough hormone. This can be due to surgical removal, radioactive iodine ablation, autoimmune destruction (Hashimoto’s disease), or glandular burnout from chronic stress.
  • Type 2 Hypothyroidism: This is a conversion problem. The body is unable to effectively convert the inactive storage hormone (T4) into the active, usable hormone (T3). This is where the standard T4-only treatment model fails.
  • Type 3 Hypothyroidism: This is a receptor issue in which cellular receptors become resistant to thyroid hormone, often due to inflammation or illness.

The thyroid gland produces a hormone called thyroxine (T4), which contains four iodine atoms. To become metabolically active, it must lose one iodine atom to become triiodothyronine (T3). T3 has five times the affinity for the thyroid receptor as T4. This means T3 is the hormone that does the heavy lifting. T4 is simply the raw material we store to make T3 whenever we need it. You live off your T3.

The Critical Flaw of TSH Testing and Deiodinase Dysfunction

The TSH test was designed as a screening test for an asymptomatic population to see if they are at risk for a thyroid condition. The inventor of the assay himself stated it was never intended to be used to monitor or guide therapy for a treated patient. So why is it the cornerstone of modern treatment? Because it makes the lab reports look good, providing a false sense of security for practitioners while patients remain unwell.

A pivotal study published by Escobar-Morreale et al. (1997) shed light on this discrepancy. Researchers discovered that the concentration of T3 varied significantly in different tissues throughout the body—the liver, kidneys, and muscles. But there was one place where T3 levels remained stable, even when they were low everywhere else: the brain.

This is because the brain and pituitary gland exhibit a unique, highly concentrated expression of the enzyme deiodinase type 2 (D2). This enzyme is responsible for converting T4 into the active T3. The rest of your body—the periphery—also uses D2, but a host of common stressors can downregulate its activity there while leaving it untouched in the pituitary.

What does this mean? It means your pituitary gland—the very organ that produces TSH—lives in a “T3 bubble,” isolated from the reality of what’s happening in the rest of your body. Your muscles, liver, and fat cells can be starving for T3, but your brain’s T3 level can remain perfectly normal. Consequently, your pituitary sees no problem and keeps the TSH level low and “normal.” Your pituitary gland has no idea what the T3 level is in your big toe, and TSH cannot tell us. This is why a patient can have a “perfect” TSH and still feel terrible.

The Roadblock: Reverse T3 and Poor Conversion

The body has a protective buffer system. Under conditions of stress, inflammation, illness, or nutrient deficiency, the body can divert T4 down a different path. Instead of converting to active T3, it uses a different enzyme, deiodinase type 3 (D3), to convert T4 into an inactive form called Reverse T3 (rT3).

Reverse T3 has the same shape as active T3, allowing it to fit into the thyroid receptor. However, it is a dud. It doesn’t turn the engine on. Instead, it sits there, blocking active T3 from getting to the receptor.

When you give a patient a large dose of T4, especially if they have underlying inflammation or stress, their body often perceives it as a threat. To protect itself from becoming overstimulated, it down-regulates D2 (making less active T3) and up-regulates D3 (making more inactive Reverse T3). The result? The patient’s TSH goes down, their labs look “good,” but their symptoms get worse because their cells are being flooded with an inactive blocker hormone.

A landmark study from Israel beautifully outlines the myriad factors that impair the conversion of T4 to T3:

  • Psychological and Physical Stress: High cortisol is a potent inhibitor.
  • Insulin Resistance and Diabetes: Poor blood sugar control disrupts thyroid function.
  • Inflammation: Cytokines from injury, infection, or chronic disease impair deiodinase enzymes.
  • Autoimmune Disease: Conditions such as Hashimoto’s cause chronic inflammation.
  • Nutrient Deficiencies: Deficiencies in key minerals like iron (ferritin) and selenium are critical cofactors for deiodinase enzymes.
  • Aging: The natural process of aging reduces conversion efficiency, as noted by Duntas & Biondi (2011).

Considering this list, it’s clear that the vast majority of people are not converting T4 to T3 optimally, creating an epidemic of subclinical, functional hypothyroidism.

The Heart of the Matter: Low T3 Syndrome and Cardiovascular Risk

The medical field that has most urgently recognized the danger of this condition is cardiology. An overwhelming body of research now links Low T3 Syndrome directly to poor outcomes in cardiovascular disease. A landmark study by Iervasi et al. (2003) found that in patients with heart disease, a low T3 level was a strong prognostic predictor of death, whereas TSH had no predictive value.

Why is this the case? The myocardium, or heart muscle, is exquisitely sensitive to T3. It relies on adequate T3 for proper contractility, rhythm, and overall function. When serum T3 is low, the heart is essentially starved of its primary metabolic fuel. Historically, how did patients with profound, untreated hypothyroidism die? Almost universally from cardiovascular events. A healthy Free T3 level is a critical component of cardiovascular protection. Patients in the lower part of the lab reference range can have a 33% to 66% higher risk of all-cause and cardiovascular mortality compared to those in the upper range (Pingitore, Iervasi, & Chopra, 2008).

The Problem with “Normal”: Redefining Lab Reference Ranges

This brings me to a fundamental problem in conventional medicine: our reliance on statistically “normal” reference ranges. Let’s say the lab reference range for Free T3 is 2.2 to 4.2 pg/mL. A patient comes to me with a level of 2.3 pg/mL. They have been told their thyroid is “normal.” Yet, they are exhausted, their hair is falling out, and they can’t lose weight.

What does being in the 10th percentile of the reference range truly mean? It means 90% of the population has more of this vital, energy-giving hormone than you do. Does that sound optimal? Of course not. My approach is to move patients from the bottom of the range to a more optimal position, typically aiming for the top quartile (75th percentile and above). I am not treating a lab number; I am treating a patient.

A Modern, Evidence-Based Treatment Protocol

So, how do we put all this knowledge into practice? Here is the approach I use, which is grounded in the latest research and my clinical experience.

1. Comprehensive Lab Testing

A TSH-only screen is inadequate. I order a full panel that includes TSH, Free T4, Free T3, and Thyroid Antibodies (TPO and TgAb). If a patient is on T4-only medication and still has symptoms, I always order a Reverse T3 (RT3) test. This panel gives us the complete picture.

2. Choosing the Right Medication

The evidence and patient satisfaction surveys point to a clear conclusion: T4-only therapy is not effective for a significant portion of the population. A 2018 online survey of over 12,000 thyroid patients found that those taking Natural Desiccated Thyroid (NDT), which contains both T4 and T3 (such as NP Thyroid or Armor Thyroid), reported significantly higher satisfaction with their treatment (Peterson et al., 2018).

NDT is derived from porcine thyroid glands and contains T4 and T3 in a ratio very similar to the human thyroid. It provides the body with the active hormone it needs directly, bypassing potential conversion issues. When transitioning a patient from a synthetic T4 medication, I use a careful overlap protocol to allow the body to acclimate smoothly.

3. Standardizing Lab Draws and Dosing

T3 has a very short half-life of about 18-24 hours. To obtain meaningful and consistent data, testing must be standardized. I instruct all my patients to have their blood drawn five to six hours after taking their morning dose. This provides us with a consistent point on the absorption curve.

For my patients with Type 1 hypothyroidism—those without a functioning thyroid—a significant breakthrough has been the introduction of a second, afternoon dose of NDT. Because of T3’s short half-life, a single morning dose often leads to a “crash” by 3 or 4 p.m. By splitting their total daily dose, we maintain a more stable level of active T3, transforming their energy and quality of life.

The Critical, Overlooked Role of Iodine

I cannot overstate the importance of iodine for thyroid health and overall well-being. The Recommended Dietary Allowance (RDA) in the U.S. is a mere 150 micrograms, an amount established simply to prevent goiter, not to promote optimal health. In stark contrast, the average daily intake of iodine in Japan is over 13 milligrams (13,000 micrograms), primarily from seaweed. The correlation with cancer rates is alarming; Japan has significantly lower rates of breast and prostate cancer. As Dr. David Brownstein explains in his book, Iodine: Why You Need It, Why You Can’t Live Without It, this is likely not a coincidence.

Iodine is essential not just for the thyroid but for breast tissue, the prostate, ovaries, and every cell in the body. When you begin supplementing an iodine-deficient person, TSH will temporarily rise. This is the body’s intelligent response to produce more sodium-iodide symporters (NIS)—the gateways that pull iodine into the cells. An uninformed practitioner might see this TSH spike and wrongly conclude that the iodine is harmful. This is why I tell my patients we will not check a TSH level for at least nine months after starting iodine therapy. Free T3 and the patient’s symptoms are our true guides.

Integrative Chiropractic Care: The Neurological Connection

As a Doctor of Chiropractic (DC), I view the body through the lens of the nervous system as the master controller of all other systems, including the endocrine system. The connection among the spine, the nervous system, and thyroid function is a critical yet often-overlooked piece of the puzzle.

The thyroid gland receives its nerve supply from the cervical spine. Misalignments, or vertebral subluxations, in this area can interfere with the nerve signals traveling between the brain and the thyroid. This can disrupt the delicate feedback loop of the hypothalamic-pituitary-thyroid (HPT) axis.

How Chiropractic Fits In:

  • Restoring Nerve Function: Through specific, gentle chiropractic adjustments, we can correct subluxations in the cervical spine. This restores proper nerve flow, ensuring the brain and thyroid can communicate effectively. In my clinic, I have observed that patients receiving regular chiropractic care often see improvements in their thyroid function.
  • Reducing Systemic Stress: The chiropractic adjustment has a powerful effect on the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. Chronic stress elevates cortisol levels, which inhibit the conversion of T4 to T3. By modulating the stress response through chiropractic care, we create a more favorable hormonal environment for optimal thyroid function.
  • Holistic Support: Integrative chiropractic care encompasses nutritional counseling, lifestyle recommendations, and stress management techniques, all of which are foundational to supporting endocrine health.

By integrating chiropractic adjustments with functional medicine protocols, we address both the biochemical and neurological aspects of thyroid dysfunction, providing a truly comprehensive and powerful path to healing. Ultimately, our goal is not just to fix a lab value. It is to listen to our patients, to understand the deep physiological imbalances at play, and to use every evidence-based tool at our disposal to restore health and change lives.

References

Brownstein, D. (2014). Iodine: Why you need it, why you can’t live without it (5th ed.). Medical Alternatives Press.

Duntas, L. H., & Biondi, B. (2011). The aging thyroid: a challenge for the clinician. Nature Reviews Endocrinology, 7(9), 558–560. https://www.nature.com/articles/nrendo.2011.83

Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1997). Tissue-specific patterns of changes in 3,5,3′-triiodothyronine concentrations in hypothyroid rats. Endocrinology, 138(6), 2494-2503. https://doi.org/10.1210/endo.138.6.5186

Guo, T., Wang, Y., Zhang, Y., Ma, J., & Wang, F. (2022). Lower free triiodothyronine levels are associated with major depressive disorder and its symptom severity. Psychoneuroendocrinology, 146, 105952. https://doi.org/10.1016/j.psyneuen.2022.105952

Iervasi, G., Pingitore, A., Landi, P., Raciti, M., Ripoli, A., Scarlattini, M., L’Abbate, A., & Donato, L. (2003). Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 107(5), 708–713. https://www.ahajournals.org/doi/10.1161/01.cir.0000048039.63811.23

Peeters, R. P., Wouters, P. J., van Toor, H., Kaptein, E., Visser, T. J., & Van den Berghe, G. (2003). Serum 3,3′,5′-triiodothyronine (rT3) and 3,5,3′-triiodothyronine/rT3 are prognostic markers in critically ill patients and are associated with postmortem tissue deiodinase activities. The Journal of Clinical Endocrinology & Metabolism, 88(10), 4559–4565. https://academic.oup.com/jcem/article/88/10/4559/2845213

Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hescox, M., & … Bianco, A. C. (2018). An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid, 28(6), 707–721. https://doi.org/10.1089/thy.2017.0681

Pingitore, A., Iervasi, G., & Chopra, I. J. (2008). The role of thyroid hormone in the heart. Journal of Clinical Endocrinology & Metabolism, 93(6), 1957–1964.

Shakir, M. K., Brooks, B. A., & Crooks, L. A. (2007). The significance of a suppressed TSH in hypothyroid patients on levothyroxine. Endocrine Practice, 13(1), 16-20. https://doi.org/10.4158/EP.13.1.16

Starr, M. (2005). Hypothyroidism Type 2: The epidemic. Mark Starr Trust.

Woeber, K. A. (2002). Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations. Journal of Endocrinology and Metabolism, 87(9), 3986-3990. https://doi.org/10.1210/jc.2002-020580

A Smarter Path to Hormonal Health and Vitality

A Smarter Path to Hormonal Health and Vitality

A Smarter Path to Hormonal Health and Vitality
Health: doctor visit with patient, medical exam, hospital visit, and conversation about bioidentical hormone replacement therapy.

Abstract

Welcome. As a clinician with a diverse background in chiropractic, advanced practice nursing, and functional medicine, I am deeply committed to an integrative, evidence-based approach to health. This educational post will guide you through the intricate and often misunderstood world of hormones, debunking long-held myths and presenting a modern, holistic paradigm for wellness. We will critically re-examine the flawed Women’s Health Initiative (WHI) study, exposing how the use of synthetic hormones and improper delivery systems created a legacy of fear. We will explore the profound differences between bioidentical progesterone and synthetic progestins and present compelling data that vindicates estrogen, revealing its protective role against breast cancer. This journey will also dismantle myths surrounding testosterone, clarifying its crucial role in both men and women for cognitive function, mental health, cardiovascular wellness, and pain management. We will explore the physiological underpinnings of bone health, contrasting outdated bisphosphonate therapies with a superior, hormone-centric approach. Throughout this discussion, I will integrate the principles of integrative chiropractic care, demonstrating how restoring structural and neurological integrity is foundational to achieving optimal hormonal balance and preventing the chronic diseases of aging. My goal is to empower you with knowledge, moving from fear and misinformation to clarity and confidence in your health decisions.

Unraveling the Women’s Health Initiative: A Critical Re-Examination

Let’s begin by asking a fundamental question: Why are you here, reading this today? Perhaps it’s because the conventional health approaches you’ve encountered haven’t provided the answers or the well-being you’re seeking. This is a common story in my practice. People feel unwell, unheard, and confused by conflicting information, especially when it comes to hormones.

My journey and yours often start with a desire to understand the “why.” This is particularly true when we look at the history of hormone replacement therapy (HRT). Let’s travel back to the pivotal Women’s Health Initiative (WHI) study, a trial whose initial results, reported in 2002, radically altered our perception of hormones and left a legacy of fear that persists to this day.

But what if the study’s foundation was flawed from the start? Let’s consider a hypothetical. What if the WHI had used 17-beta estradiol delivered via a non-oral route, like a patch, instead of oral conjugated equine estrogens (Premarin)? And what if they had used bioidentical progesterone instead of a synthetic progestin like medroxyprogesterone acetate (Provera)?

The Critical Importance of Delivery Systems and Molecular Structure

To understand why this distinction is so crucial, we must look at our physiology. When you take a hormone in an oral pill form, it undergoes first-pass metabolism in the liver.

  • Portal Circulation: Blood from your intestines goes directly to the liver through the portal vein.
  • Liver Metabolism: The liver works hard to process this concentrated dose of the oral hormone. In response, it produces other substances, including an increased amount of clotting factors.
  • Increased Clotting Risk: This is precisely why oral estrogen, found in medications like birth control pills and Premarin, is associated with an elevated risk of blood clots.

One of the most important benefits of estrogen is its cardioprotective effect. However, administering it orally simultaneously increases clotting factors, effectively canceling that benefit, since most heart attacks and strokes involve clot formation. The WHI concluded that estrogen didn’t help, but the reality is that they were using the wrong molecule (conjugated equine estrogens) and the wrong delivery system (oral). Had the study used 17-beta estradiol—the exact molecule our bodies are designed to use—and administered it transdermally, bypassing intensive liver metabolism, the outcomes would have been dramatically different.

Now, let’s look at progesterone. Has natural, bioidentical progesterone ever been shown to increase the risk of breast cancer in any credible study? The answer is a resounding no. The WHI used a synthetic progestin, Provera. We wouldn’t be having this conversation today if we had used the correct hormone molecules and delivery systems. The standard of care would be clear: as soon as a woman enters menopause, she should begin estrogen and progesterone therapy for the long-term health of her heart, bones, and brain.

The Lasting Impact and Ultimate Vindication of Estrogen

I was in private practice when the 2002 WHI results were published in the Journal of the American Medical Association (JAMA) and splashed across the cover of TIME magazine. Fear sells. The report, titled “The Truth About Hormones,” scared millions of women. I had to hire an additional staff member just to field panicked calls from patients wanting to stop their hormones.

In my clinical practice at our Chiropractic & Functional Medicine Clinic, I see the downstream effects every day. How many women today are suffering from cognitive decline, osteoporosis, and heart disease that could have been mitigated? Depriving an entire generation of women of protective estrogen has had devastating consequences.

The story gets even more compelling over time. Follow-up reports on the same WHI cohort have been nothing short of vindicating for estrogen.

  • An 18-year follow-up published in JAMA stated, “Estrogen plus progestin was not associated with increased all-cause, cardiovascular, or cancer mortality…” (Manson et al., 2017). Essentially, the researchers were saying, “Never mind.”
  • A 2020 study, also in JAMA, delivered a bombshell. Women in the estrogen-only arm for about seven years had a lower incidence of breast cancer and were less likely to die from breast cancer over their lifetimes (Chlebowski et al., 2020).

Let that sink in. Estrogen is the only medicine in history shown in a prospective, randomized, placebo-controlled, long-term trial to reduce the chance of both getting breast cancer and dying from it. And this result was with Premarin, a “dirty” estrogen. Imagine the protective power of bioidentical 17-beta estradiol.

Understanding Progesterone vs. Progestins: A Critical Distinction

It is critically important to distinguish between progesterone and progestins. They are not the same, and this confusion is at the heart of much of the misinformation surrounding HRT.

  • Progesterone (P4): This is the natural, bioidentical hormone our bodies produce. It has a specific, beneficial molecular structure.
  • Progestins: These are synthetic compounds designed to mimic some of the effects of progesterone. Examples include medroxyprogesterone acetate and norethindrone acetate. They have different molecular structures and vastly different metabolic effects.

When I see a new study claiming “hormone replacement therapy” causes a health issue, the first thing I do is look at the abstract to identify the molecules used. Invariably, the culprit is a synthetic progestin.

Progesterone’s role is often tragically minimized, especially in women who have had a hysterectomy. The conventional thinking, “No uterus, no need for progesterone,” is a fundamentally flawed and harmful perspective. It ignores the progesterone receptors in the brain, bones, and cardiovascular system. In my clinical practice, every menopausal patient is on progesterone at some point. If a woman presents with insomnia, I frequently initiate treatment with progesterone, as it is unequivocally the most effective remedy for insomnia in menopausal women.

A crucial point of caution: progesterone cream is not sufficient for uterine protection. Progesterone is a large molecule that does not absorb well through the skin to achieve adequate systemic blood levels. If a uterus is present, progesterone must be delivered systemically—orally, sublingually, or as a vaginal suppository—to ensure the uterine lining is protected from the proliferative effects of unopposed estrogen (Hargrove et al., 1989).

The Menstrual Cycle: A Symphony of Hormones

To appreciate the role of hormones, we must understand their natural rhythm. The menstrual cycle is a beautiful, synergistic dance, not a battle for dominance.

  1. Follicular Phase (First Half): As a dominant follicle grows, it produces estrogen, which causes the uterine lining (endometrium) to thicken.
  2. Luteal Phase (Second Half): After ovulation, the corpus luteum produces progesterone. Progesterone’s role is to stabilize the endometrium, halting estrogen-driven proliferation and preparing the tissue for implantation.
  3. Menstruation: If implantation does not occur, the drop in progesterone triggers the shedding of the uterine lining.

It’s a mistake to say that progesterone “opposes” estrogen. They work synergistically as a team. Studying a hormone in isolation will never provide a complete understanding of its effects.

Testosterone: A Human Hormone Essential for All

One of the most persistent myths is that testosterone is exclusively a male hormone. Let’s set the record straight: testosterone is a human hormone.

  • A woman produces more testosterone over her lifetime than she does estrogen.
  • The androgen receptor is located on the X chromosome, which every individual possesses.
  • Ignoring testosterone deficiency in women, especially after a hysterectomy with ovary removal, is a grave oversight. We are taking out three essential hormones (estrogen, progesterone, and testosterone) and often replacing only one poorly.

In my practice, optimizing testosterone is crucial. It’s a key factor in managing the number one symptom of menopause: pain. Joint, bone, and muscle pain are the body’s first signals of a critical hormonal deficit.

Debunking the Myth: Testosterone and Prostate Cancer

For decades, physicians have feared that testosterone therapy is like “adding fuel to the fire” of prostate cancer. Dr. Abraham Morgentaler of Harvard traced this myth to a single, 100-year-old study of only two men. His career has been dedicated to dismantling this myth with rigorous science.

His research showed that low testosterone, not replacement therapy, is an independent risk factor for developing prostate cancer. This led to the Prostate Saturation Model. Dr. Morgentaler found that prostate androgen receptors become fully saturated at a testosterone level of around 200 ng/dL. This means that for a man with a baseline level of 350 ng/dL, optimizing his level to 950 ng/dL adds zero additional testosterone to his prostate. The receptors are already full.

The current consensus is that if a man has been successfully treated for prostate cancer and shows no evidence of recurrence, testosterone therapy can and should be initiated immediately to restore his quality of life.

Beyond “Normal”: The Power of Hormone Optimization

One of the most profound shifts in modern functional medicine is the move from the “normal range” to the “optimal range.” A lab’s reference range is just a statistical average; it says nothing about what is healthy.

A study on dementia found that men with testosterone levels in the lowest quintile had an 80% higher risk of developing dementia than men in the highest quintile (Yeap et al., 2021). A man with a “low normal” level of 325 ng/dL has a significantly higher risk than a man at an optimal 850 ng/dL. There is only suboptimal and optimal.

My goal is to restore a patient’s hormone levels to the upper quartile of the range for a young, healthy adult—a level that is protective against disease and promotes vitality.

The Receptor Model of Cancer and the Protective Role of Hormones

To understand why old fears were misplaced, we must look at the cellular level. The Receptor Model for Cancer explains that hormones exert their effects by binding to specific receptors. The problem arises with synthetic molecules like progestins, which can block protective receptor pathways, effectively removing the brakes on cell growth.

This is what happened in the WHI. The synthetic progestin blocked protective pathways, leading to an observed increase in breast cancer. It wasn’t the estrogen; it was the progestin.

In stark contrast, compelling evidence shows that testosterone has anti-inflammatory and anti-proliferative (anti-cancer) effects in breast tissue. Dr. Rebecca Glaser, a breast cancer surgeon, has published extensively on this.

  • A massive Nurses’ Health Study followed nearly 30,000 nurses for 24 years. It found that women who had their ovaries removed (inducing surgical menopause) had a significantly higher risk of all-cause mortality, heart disease, and lung cancer compared to those who conserved their ovaries (Parker et al., 2013). Our natural hormones provide powerful, lifelong protection.

Rethinking Osteoporosis: Hormones for Bone Health

The conventional approach to osteoporosis, using drugs like bisphosphonates, is deeply flawed. These drugs work by blocking osteoclasts, the cells that break down old bone. This is like paving over a road full of potholes without clearing out the crumbling asphalt. You accumulate old, weak, brittle bone that may look denser on a scan but is not structurally sound.

The true key is promoting healthy bone remodeling, and hormones are the master regulators. A landmark study showed that patients on hormone pellet therapy experienced an average 8.3% increase in bone density per year. This vastly outperforms bisphosphonates (1-2% annual increase). By restoring hormonal levels of estrogen and testosterone, we effectively turn back the clock on skeletal health.

Testosterone and the Heart: A Cardiologist’s Best Friend

One of the most dangerous myths is that testosterone is bad for the heart. This scare originated from a thoroughly debunked 2016 VA study that used a flawed high-risk population and manipulated data to reverse its own raw findings.

The scientific reality is that low testosterone is an independent risk factor for cardiovascular disease. Optimal testosterone is a cardiologist’s best friend because it:

  • Improves endothelial function, keeping arteries smooth.
  • Increases arterial elasticity, helping regulate blood pressure.
  • Enhances insulin sensitivity, a primary driver of heart disease.
  • Exerts anti-inflammatory effects, quelling the inflammation that underlies heart attacks.

Integrative Chiropractic Care: Restoring Foundational Health

This is where the principles of integrative chiropractic care and functional medicine become so vital. The body is an interconnected system where structure governs function. Hormonal balance cannot be fully achieved if the underlying neurological and structural systems are compromised.

  • Nervous System Regulation: The endocrine system is under the direct control of the nervous system. Chiropractic adjustments correct spinal misalignments (subluxations), restoring proper nerve flow between the brain and the endocrine glands. This optimizes the function of the hypothalamic-pituitary-adrenal-ovarian (HPAO) axis, the master communication network governing hormone production.
  • Stress Reduction: Adjustments can shift the autonomic nervous system from a dominant “fight-or-flight” (sympathetic) state to a more relaxed “rest-and-digest” (parasympathetic) state. This is crucial because chronic stress elevates cortisol, which can disrupt the entire endocrine system and steal the building blocks for sex hormone production.
  • Holistic Assessment: As a Doctor of Chiropractic, I have a comprehensive understanding of the situation. Low back pain may be connected to fatigue, low mood, systemic inflammation, and hormonal imbalance. This integrative perspective allows me to educate patients on the connections between their spine, nervous system, and hormonal health.

By combining evidence-based hormone optimization with the foundational principles of chiropractic care, we address the root cause of dysfunction. We don’t just replace a missing hormone; we restore the body’s innate intelligence and create a synergistic effect for true, resilient health. This is the future of healthcare—a proactive, personalized, and integrative approach that empowers you to live a longer, healthier, and more vibrant life.

References

Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380.

Hargrove, J. T., Maxson, W. S., Wentz, A. C., & Burnett, L. S. (1989). Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstetrics and Gynecology, 73(4), 606–612.

Manson, J. E., Aragaki, A. K., Rossouw, J. E., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938.

Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., & Manson, J. E. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstetrics and Gynecology, 121(4), 709–716.

Yeap, B. B., Flicker, L., Xiao, J., Norman, P. E., Hankey, G. J., Almeida, O. P., & Almeida, O. (2021). Associations of sex hormones with incident dementia and cognitive decline in older men: The Health in Men Study. The Journal of Clinical Endocrinology & Metabolism, 106(4), 1042-1054.

Insights for Androgen Hormone Optimization & Chronic Diseases

Discover how androgen hormone optimization for chronic diseases affects your body and find solutions for improved health.

Abstract

As a clinician, educator, and researcher, I work at the intersection of physiology and patient outcomes. In this educational post, I, Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, present a comprehensive, first-person synthesis of how balanced androgen and estrogen signaling shapes brain function, bone remodeling, cardiovascular and metabolic resilience, sexual health, and cancer risk. I explain the androgen receptor (AR) and estrogen receptor (ER) biology that underpins modern practice, why aromatization to estradiol and 5α-reduction to dihydrotestosterone (DHT) are essential—not side pathways—and how the prostate saturation model reframes longstanding myths about testosterone and prostate cancer. I detail how I evaluate and optimize testosterone replacement therapy (TRT) for men and physiologic androgen support for women, including when to prefer transdermal estradiol, how to monitor free testosterone and sex hormone–binding globulin (SHBG), and how to protect safety by tracking hematocrit, PSA, and metabolic markers. I also address nuanced areas such as opioid-induced androgen deficiency, androgen support in women with elevated SHBG, and receptor-informed reasoning for breast and prostate cancer risk. Throughout, I highlight peer-reviewed evidence from leading researchers and integrate clinical observations from my work at chiromed.com and my professional updates at LinkedIn, to empower patients and clinicians to make informed, physiology-respecting decisions.

Hormone Physiology 101: Why Androgens and Estrogens Work Better Together

In every tissue I examine—brain, bone, heart, muscle, skin—the conversation between androgens and estrogens is continuous and collaborative. Testosterone occupies a central node in this conversation because it acts:
By directly activating the androgen receptor (AR) to drive protein synthesis, erythropoiesis, endothelial function, and neuromodulation.
It aromatizes to estradiol (E2), which is indispensable for bone mineral density, synaptic plasticity, and vascular flexibility.
By 5α-reducing to dihydrotestosterone (DHT), a higher-affinity AR ligand that supports sexual function, mood, and neurovascular stability.
These conversions are not waste; they are physiological amplifiers that tune responses by tissue. When clinicians indiscriminately block aromatase or 5α-reductase, patients can lose essential downstream signaling. I frequently see men who arrive on a 5α-reductase inhibitor for hair loss and an SSRI for premature ejaculation with near-zero DHT and low E2. The clinical picture—profound loss of libido, erectile dysfunction, emotional blunting—matches what the physiology predicts: too little AR and ER engagement. Respecting these pathways and restoring balanced AR/E2 signaling is often the turning point.
Clinical takeaway
Bold principle: Do not reflexively block physiological androgen conversions; treat the person, not just the lab number.
References: Bhasin et al., 2018

The Case for Testosterone Optimization in Men and Women

When hypogonadism is accurately diagnosed and treatment is monitored, physiological TRT is associated with meaningful improvements across systems:
Cardiovascular and vascular function
Improved endothelial nitric oxide signaling, decreased inflammatory tone, and improved body composition correlate with neutral-to-favorable cardiovascular outcomes in hypogonadal men whose testosterone is brought back to physiologic ranges (Bhasin et al., 2018; Corona et al., 2018; Khera et al., 2020).
Metabolic health
Androgens enhance insulin signaling and reduce visceral adiposity; TRT can improve glycemic control and metabolic syndrome features in androgen-deficient men (Corona et al., 2018).
Mood and cognition
AR signaling influences dopaminergic and serotonergic networks. Restoring deficient testosterone often improves vitality and depressive symptoms (Walther et al., 2019).
Sexual function
Physiologic TRT improves desire and erectile quality through both AR and nitric oxide pathways.
Bone and muscle
Estradiol derived from testosterone is essential for bone remodeling, while AR signaling drives muscle protein synthesis and strength.
For women, carefully dosed physiologic testosterone can improve desire, arousal, energy, and cognition when free testosterone is low—particularly when SHBG is high and blunts receptor access. While FDA-approved options for women are limited in the U.S., off-label, evidence-based protocols are supported by position statements and RCT meta-analyses (Davis et al., 2019; Islam et al., 2019).
References: Bhasin et al., 2018; Corona et al., 2018; Walther et al., 2019; Davis et al., 2019; Islam et al., 2019; Khera et al., 2020

Prostate Health and the Saturation Model: Reframing an Old Myth

For decades, clinical teaching suggested testosterone “fuels” prostate cancer. Modern evidence, led by Dr. Abraham Morgentaler and colleagues, paints a more precise picture:
Saturation model
Prostate ARs saturate at relatively modest serum testosterone concentrations. Above this threshold, additional testosterone does not linearly increase intraprostatic signaling (Morgentaler & Traish, 2009).
Practical point: Men with low-to-mid “normal” serum T typically have near-maximal intraprostatic AR occupancy; moving from low to mid-physiologic ranges does not predict proportional PSA rises or cancer risk. If PSA rises significantly on TRT, investigate prostatitis, occult malignancy, or other drivers—do not simply assume “testosterone did it.”
Low testosterone as a risk marker
Observational data associate lower baseline testosterone with higher-grade disease at diagnosis and worse prognostic indicators (Morgentaler, 2006; Isbarn et al., 2009).
In properly selected men treated for localized prostate cancer with no evidence of disease, carefully monitored TRT has not shown increased recurrence in multiple series (Pastuszak et al., 2013).
My practice experience
Men with symptomatic hypogonadism and benign prostatic hyperplasia (BPH), when cancer-negative, deserve a nuanced TRT discussion. In my clinic, treating physiologic targets rarely worsens lower urinary tract symptoms. If symptoms worsen, I look for other causes.
References: Morgentaler & Traish, 2009; Morgentaler, 2006; Pastuszak et al., 2013

Androgen Deprivation Therapy: Cognitive and Cardiometabolic Costs

Androgen deprivation therapy (ADT) remains important for advanced or high-risk prostate cancer. However, the systemic costs are not trivial:
Cognition
Observational studies link ADT with higher risks of cognitive decline and Alzheimer’s disease (Nead et al., 2017).
Cardiometabolic health
ADT worsens insulin resistance, increases visceral adiposity, depresses endothelial nitric oxide, and increases cardiovascular events (Zhao et al., 2014).
Bone and muscle
Accelerated bone loss and sarcopenia occur in the absence of androgen and estradiol signaling.
Where oncologically feasible, I favor organ-directed strategies without prolonged systemic hormone suppression, particularly in men with high cardiometabolic risk. When ADT is required, we proactively mitigate risk: progressive resistance training, vitamin D and calcium, bone-protective agents when indicated, nutrition, sleep optimization, and close cardiovascular monitoring.
References: Nead et al., 2017; Zhao et al., 2014

Normal vs Optimal: Why Reference Ranges Are Not Targets

A reference range reflects where 95% of the sampled population falls; it does not define the zone of optimal health. For hormones that decline with age, “normal” skews lower as the population ages and accrues comorbidities.
Evidence signal
Meta-analytic and cohort data link low-quantile testosterone in men with significantly higher risk of all-cause dementia and Alzheimer’s disease—even when values sit within “normal” lab ranges (Chu et al., 2020).
Clinical principle
I aim for optimal physiological targets based on outcomes—not merely clearing the lower bound of normal. For symptomatic men, that often means the upper half of physiologic ranges, provided safety metrics remain favorable.
References: Chu et al., 2020

Women, Androgens, and SHBG: Treating What Cells “Feel,” Not Just What Labs Print

Women rely on ovarian and adrenal androgens for sexual desire, arousal, bone and muscle integrity, and cognitive drive. The clinical challenge I see daily is high SHBG—especially with oral estrogens, certain medications (including SSRIs), thyroid shifts, or liver changes—binding testosterone and shrinking the free/bioavailable fraction that actually reaches receptors.
Why women feel “not themselves” with “normal” labs
A “normal” total testosterone level with high SHBG can mean low free testosterone at the receptor level. Symptoms—low desire, fatigue, cognitive fog, diminished exercise capacity—reflect a genuine female androgen deficiency despite a normal total.
My approach
I prioritize free testosterone (equilibrium dialysis or validated calculation) and SHBG, not just total testosterone, and titrate to physiologic free levels that resolve symptoms while monitoring for side effects.
Pellets and transdermal therapy
For select women, bioidentical testosterone pellets provide steady pharmacokinetics that overcome high SHBG, improve adherence, and stabilize symptoms. For others, transdermal formulations enable flexible titration. The goal is normal receptor-level exposure, not elevated totals per se.
References: Davis et al., 2019; Islam et al., 2019; Parish et al., 2021

Breast, Prostate, and Receptor Biology: A Practical Lens for Risk

The most durable way to reason about cancer risk in hormone care is through receptor biology.
ER-alpha vs ER-beta
ER-alpha activation in breast tissue often increases BCL-2 (cell survival), while ER-beta tends to promote differentiation and apoptosis; estrone (E1), produced in adipose tissue, favors ER-alpha, especially in obesity (Jordan, 2014; Yasuda et al., 2020).
Androgen receptor in breast tissue
AR activation can counter ER-alpha-driven proliferation and reduce BCL-2 in the breast epithelium, providing a mechanistic basis for the anti-proliferative effects of androgens in certain contexts (D’Amato et al., 2020).
Progesterone vs progestins
Bioidentical progesterone has tissue-specific effects through PRA/PRB; some synthetic progestins (e.g., medroxyprogesterone acetate) interact adversely with AR and glucocorticoid receptors, contributing to discordant risk profiles (Sitruk-Ware & Plu-Bureau, 2018; Stute et al., 2016).
Practical implications in my clinic
In postmenopausal women with metabolic risk and estrone dominance, I emphasize weight loss, insulin sensitization, and, when indicated, transdermal estradiol plus bioidentical progesterone for endometrial protection. When women cannot use estrogen (e.g., certain oncology contexts), physiologic testosterone support—coordinated with oncology when applicable—can improve quality of life and adherence to aromatase inhibitors without evidence of increased breast cancer incidence at physiologic dosing.
References: Jordan, 2014; Yasuda et al., 2020; D’Amato et al., 2020; Sitruk-Ware & Plu-Bureau, 2018; Stute et al., 2016

Why Route Matters: Transdermal Estradiol and Vascular Safety

When I choose estrogen therapy, I often favor transdermal estradiol:
Avoid first-pass hepatic burden
Oral estrogens upregulate hepatic clotting factors and CRP and skew metabolite profiles, while transdermal routes deliver steady E2 with fewer hepatic effects (Canonico et al., 2007; Scarabin, 2018).
Brain and bone access
Transdermal estradiol supports consistent receptor engagement in the brain and bone, aligning with the goals of mood stabilization and bone remodeling.
To protect the endometrium in women with a uterus, I pair transdermal estradiol with micronized progesterone, which also assists sleep via GABAergic metabolites.
References: Canonico et al., 2007; Scarabin, 2018

Mechanisms That Explain Clinical Gains: Brain, Heart, Metabolism, Bone, and Muscle

Understanding the mechanism strengthens clinical decisions:
Brain
Estradiol and androgens modulate glutamatergic/GABAergic balance, upregulate BDNF, and reduce neuroinflammation; AR signaling enhances mesolimbic dopamine pathways relevant to motivation and mood (Albert et al., 2015; Kulkarni et al., 2022).
Cardiovascular system
Physiologic testosterone and estradiol increase eNOS activity and nitric oxide, reduce endothelin-1 and inflammatory adhesion molecules, and improve microvascular function (Vitali et al., 2014; Wu et al., 2018).
Metabolism
AR signaling increases insulin-stimulated GLUT4 translocation and PI3K/Akt activity in skeletal muscle, enhancing metabolic flexibility; normalization of T improves TG/HDL ratios and lowers hs-CRP in many patients (Kelly & Jones, 2015; Grossmann, 2011).
Bone and muscle
Estradiol is pivotal for osteoclast apoptosis and osteoblast survival; AR signaling via mTOR pathways supports muscle protein synthesis (Khosla & Monroe, 2018; Falahati-Nini et al., 2000).
References: Albert et al., 2015; Kulkarni et al., 2022; Vitali et al., 2014; Wu et al., 2018; Kelly & Jones, 2015; Grossmann, 2011; Khosla & Monroe, 2018; Falahati-Nini et al., 2000

My Stepwise Protocol: How I Evaluate, Treat, and Monitor Hormone Health

I align therapy with physiology and outcomes, not just numbers:
Baseline evaluation
Symptoms: libido, sexual function, energy, sleep, mood, cognitive clarity; in men, lower urinary tract symptoms; in women, menopausal status and vasomotor load.
Labs: total and free testosterone, SHBG, estradiol (sensitive assay in men; appropriate assay in women), LH/FSH, prolactin, thyroid panel, fasting insulin/glucose or A1c, lipid profile, CBC (hematocrit), CMP, PSA (men), vitamin D.
Reasoning: Distinguish primary vs secondary hypogonadism, quantify aromatization potential (e.g., via SHBG, adiposity), and set safety baselines.
Formulation and dosing
Men: weekly testosterone cypionate injections to minimize peak levels; transdermal gels/creams or pellets, based on lifestyle and response.
Women: low-dose transdermal or pellet therapy when indicated; anchor dosing on free testosterone and response.
Reasoning: Match pharmacokinetics to patient needs; avoid supraphysiologic peaks that increase the risk of side effects.
Preserve physiological conversions
Avoid routine 5α-reductase blockade; monitor estradiol levels and support weight loss and resistance training to balance aromatization; modulate aromatase only cautiously when clinically necessary.
Reasoning: DHT and E2 are beneficial at physiologic levels; suppression can worsen joints, libido, and mood.
Monitoring cadence
4–8 weeks post-initiation or dose change: trough testosterone, estradiol, hematocrit, PSA (men), blood pressure, symptoms.
3–6 months: reassess labs and adjust to align symptom relief with optimal ranges.
Stable phase: semiannual to annual follow-up.
Safety management
Hematocrit: adjust dose/route; split dosing; treat sleep apnea; consider therapeutic phlebotomy if appropriate.
PSA: Investigate unexpected rises with urology; do not reflexively blame TRT.
Lipids/glucose: manage with lifestyle and medications when needed.
References: Bhasin et al., 2018

Depression, Drive, and the Androgen–Mood Connection

The neurobiology is clear: ARs in prefrontal and limbic networks cross-talk with dopamine and serotonin. In practice, low androgen states often present with low drive, anhedonia, irritability, and sleep disruption. Randomized and observational studies show that restoring physiologic testosterone in androgen-deficient adults improves depressive symptoms and vitality (Walther et al., 2019). In my clinic, when hormones are corrected, patients often re-engage more effectively with psychotherapy and lifestyle change—because biological capacity underpins behavior.
References: Walther et al., 2019

Clinical Cases I See Repeatedly

Young man, post 5α-reductase inhibitor
Presentation: low libido, ED, tearfulness; labs show mid-range total T, near-zero DHT, and low estradiol.
Plan: stop unnecessary blockade, initiate low-dose weekly TRT, restore DHT and E2 levels to normal ranges; add resistance training and sleep optimization.
Outcome: libido, erections, and mood rebound within 8–12 weeks.
Midlife man with metabolic syndrome
Presentation: low-normal T, obesity, prediabetes, cognitive “fog.”
Plan: weekly TRT, nutrition, progressive resistance training; dose-splitting to control hematocrit.
Outcome: improved A1c, reduced waist, sharper concentration, better sleep.
Perimenopausal woman with high SHBG
Presentation: low desire, poor recovery, brain fog; normal total T with elevated SHBG and low free T.
Plan: transdermal or pellet testosterone titrated to physiologic free T; optimize estradiol and progesterone as indicated.
Outcome: improved focus, spontaneous desire, and stronger training performance within 6–8 weeks.

Opioid-Induced Androgen Deficiency: Breaking the Pain Cycle

Chronic opioids suppress the hypothalamic–pituitary–gonadal axis, leading to opioid-induced androgen deficiency (OPIAD). The result is higher pain perception, sarcopenia, sleep fragmentation, and depression—driving higher opioid doses and further suppression.
My protocol
Screen with morning total and free testosterone, SHBG, LH/FSH, prolactin, thyroid, vitamin D, and iron studies.
Replace androgens when deficiency is documented; coordinate pain management; implement resistance training, sleep therapy, and non-opioid analgesic strategies.
Outcome: improved pain thresholds, physical function, and capacity to reduce opioid reliance (Daniell, 2006; Rubinstein & Carpenter, 2014).
References: Daniell, 2006; Rubinstein & Carpenter, 2014

Bone Health: Integrating Estradiol, Testosterone, Vitamin D3, and K2

I pair hormone optimization with vitamin D3 and vitamin K2 in patients at risk for bone loss.
Mechanisms
Estradiol shortens osteoclast lifespan, supports osteoblast survival; testosterone stimulates osteoblast differentiation and periosteal formation and aromatizes locally to estradiol in bone; vitamin D3 improves calcium absorption; vitamin K2 gamma-carboxylates osteocalcin for proper mineralization (Khosla & Monroe, 2018; Falahati-Nini et al., 2000; Schwalfenberg, 2017).
Clinical practice
I order DXA every 2–3 years, depending on risk and therapy changes; I often see stabilization or improvement when patients adhere to transdermal estradiol (as indicated), physiologic testosterone (in men and select women), D3/K2, and resistance training.
References: Khosla & Monroe, 2018; Falahati-Nini et al., 2000; Schwalfenberg, 2017; Black & Rosen, 2016

Cardiovascular Safety: Separating Physiologic TRT From Anabolic Abuse

Physiologic replacement of testosterone in hypogonadal patients differs fundamentally from supraphysiologic anabolic steroid use. The literature demonstrates neutral-to-favorable cardiovascular signals when therapy is kept within physiologic ranges, comorbidities are managed, and hematocrit, blood pressure, and lipids are monitored (Bhasin et al., 2018; Corona et al., 2018). Mechanistically, eNOS upregulation, anti-inflammatory shifts, and improved body composition explain observed benefits (Vitali et al., 2014).
References: Bhasin et al., 2018; Corona et al., 2018; Vitali et al., 2014

Ovarian Conservation, Longevity, and Androgens

Cohort data show that ovarian conservation at hysterectomy (when ovaries are normal and risk is low) is associated with lower all-cause and cardiovascular mortality (Parker et al., 2009). I counsel patients on the continuing production of androgens by postmenopausal ovaries and the downstream benefits for muscle, bone, endothelial function, and mood. When ovaries are removed, compensatory androgen strategies may be appropriate under careful evaluation.
References: Parker et al., 2009

Putting It All Together: Decision Pathway for Patients and Clinicians

Step 1: Listen for pattern recognition
Do symptoms cluster in brain, bone, metabolic, sexual, or vascular domains, suggesting androgen/estrogen deficiency?
Step 2: Establish a comprehensive baseline
Include free testosterone, SHBG, and safety labs; interpret beyond”normal ranges.”
Step 3: Align on goals and context
Discuss fertility plans (TRT can suppress spermatogenesis), prostate status, oncologic history, cardiometabolic risk, and personal priorities.
Step 4: Choose routes that respect physiology
Favor steady kinetics (weekly injections, transdermal, pellets as appropriate). Preserve necessary conversions to E2 and DHT; titrate to symptom relief within physiologic bands.
Step 5: Monitor and adapt
Use symptom instruments, labs, and imaging (DXA) to ensure benefits while maintaining safety.

My Clinic, Observations, and Ongoing Education

At my integrative clinics, the most durable outcomes occur when hormone optimization is paired with strength training, nutrition, sleep, and stress management. We quantify progress with symptom scores, labs, and imaging. When mood or cognition remains impaired despite normalized sex steroids, I look deeper: thyroid, sleep apnea, iron and B12, inflammation, or primary mood disorders warrant coordinated care.
Learn more about my clinical approach and case insights:
Clinical education and resources: https://chiromed.com/
Professional updates: https://www.linkedin.com/in/dralexjimenez/

Key Myths Revisited

Myth: Testosterone causes prostate cancer.
Evidence-based view: The saturation model and modern cohorts do not support a causal relationship; low testosterone is associated with more severe pathology at diagnosis (Morgentaler & Traish, 2009; Morgentaler, 2006).
Myth: Normal lab range equals normal health.
Evidence-based view: Reference ranges reflect populations, not optimal outcomes. Aim for outcome-informed targets (Chu et al., 2020).
Myth: DHT is always harmful.
Evidence-based view: DHT is critical for sexual and neurovascular function at physiologic levels; problems arise with dysregulated or tissue-specific excess.
Myth: TRT equals anabolic steroid abuse.
Evidence-based view: Physiologic TRT differs in pharmacology, dose, and risk from supraphysiologic steroid misuse (Bhasin et al., 2018).

Final Perspective

Hormones are not luxury biochemistry; they are foundational signals keeping neurovascular, musculoskeletal, and metabolic networks synchronized. The most reliable outcomes I see in practice occur when we:
Respect physiology and avoid reflexively blocking androgen conversions.
Aim for optimal, outcomes-based targets within physiologic ranges.
Monitor proactively with symptom instruments and safety labs.
Educate patients clearly and invite them into shared decision-making.
If you would like to explore a personalized, evidence-based hormone evaluation with careful monitoring and outcome tracking, my team and I are available through our clinical resources and professional channels listed above. This educational post was created on 2026-01-16 09:40:23 and reflects contemporary research and clinical observations as summarized by me.

References



SEO tags: testosterone therapy, androgen receptors, dihydrotestosterone DHT, estradiol aromatization, prostate saturation model, hypogonadism treatment, women and androgens, cardiovascular risk testosterone, dementia risk testosterone, ADT side effects, functional medicine hormones, TRT monitoring protocol, optimal vs normal hormone ranges, estradiol transdermal, progesterone sleep, insulin sensitivity hormones, bone density vitamin D3 K2, endothelial function nitric oxide, thyroid metabolism, opioid-induced androgen deficiency, SHBG free testosterone, bioidentical pellets, breast cancer and testosterone, evidence-based hormone therapy, Dr. Alexander Jimenez

How to Prove Your Car Accident Injuries

How to Prove Your Car Accident Injuries
A woman talks online via telemedicine with her chiropractor, who is also a nurse practitioner, about her slip-and-fall work accident injury.

A ChiroMed Guide to Fast Care, Strong Records, and Clear Documentation

After a motor vehicle accident, proving that your injuries came from the crash is not only about saying you were hurt. It is about building a clear, organized timeline that starts right after the collision and continues through diagnosis, treatment, recovery, and long-term effects. For a site like ChiroMed, this topic fits naturally, as the clinic describes itself as an integrative medicine practice in El Paso that combines chiropractic care, nurse practitioner services, rehabilitation, nutrition counseling, acupuncture, and naturopathy under one roof. ChiroMed also highlights coordinated, whole-body care for injury recovery, which is important when documentation must show both what was injured and how the injury affected daily function. (ChiroMed, n.d.-a, n.d.-d).

Why fast treatment matters after a crash

The first rule is simple: get checked as soon as possible. Many sources on injury documentation explain that early medical care establishes the first direct link between the accident and your symptoms. Waiting too long gives insurers room to argue that the injury was minor, unrelated, or already there before the crash. Several sources also warn that some injuries, especially whiplash, soft tissue damage, headaches, back pain, and even concussive symptoms, may not fully appear until hours or days later. That is why immediate evaluation and, ideally, care within about 24 to 72 hours are among the strongest steps you can take. (Georgia Spine & Orthopaedics, 2025; Mesadieu Law Firm, 2025; Dominguez Firm, 2026).

At ChiroMed, that early timing matters even more because the clinic emphasizes a multidisciplinary model. Its site explains that integrated care can reduce gaps between appointments, improve coordination, and create records that are easier for attorneys and insurance companies to follow. In other words, early care does not just protect health. It also helps create a stronger, cleaner paper trail. (ChiroMed, n.d.-d).

Step 1: Seek immediate evaluation and tell the full story

Your first visit should do more than confirm that you were hurt. It should document how the crash happened, where you feel pain, which movements worsen your symptoms, and whether you have numbness, dizziness, headaches, changes in sleep, or emotional distress. Specialized injury providers are often better at documenting musculoskeletal and soft tissue problems than a quick emergency room discharge note alone, especially when symptoms involve whiplash, neck stiffness, back pain, reduced range of motion, or radiating pain. (Georgia Spine & Orthopaedics, 2025; Wright Law Firm, 2024).

A strong first visit should record:

  • The date and time of the accident
  • The type of collision
  • Where pain started
  • What symptoms appeared later
  • What you could not do after the crash
  • What body parts need follow-up testing or treatment

That level of detail helps establish causation early. (Texas Injury Accident Lawyers, 2025; Greater Texas Orthopedic Associates, 2025).

Step 2: Build a complete paper trail

Medical records are the backbone of any injury claim. They show that the injury was real, that treatment was necessary, and that the condition changed your life. Texas-specific legal guidance stresses that records help prove three things insurers commonly question: that the accident caused the injury, that the injury is legitimate, and that the treatment was reasonable. Without that documentation, adjusters may argue that the problem existed before the crash or that the pain is exaggerated. (Texas Injury Accident Lawyers, 2025; Greater Texas Orthopedic Associates, 2025).

A strong accident file usually includes the following items. (Texas Injury Accident Lawyers, 2025; Georgia Spine & Orthopaedics, 2025).

  • Emergency room, urgent care, or first office visit notes
  • Chiropractic evaluations
  • Nurse practitioner assessments
  • Diagnostic imaging reports
  • Medication lists and prescriptions
  • Physical therapy or rehabilitation notes
  • Work restrictions
  • Bills, receipts, and referral records
  • Progress notes that show whether symptoms improved, stayed the same, or got worse

This kind of organized record makes it much harder for an insurance company to say there is no clear connection between the wreck and the injury. (Greater Texas Orthopedic Associates, 2025; Texas Injury Accident Lawyers, 2025).

Step 3: Use imaging and objective testing when needed

Symptoms matter, but objective findings often carry extra weight. Imaging tests such as X-rays, MRIs, and CT scans can show fractures, disc herniations, joint damage, and other structural problems that support your claim. Legal guidance on injury causation consistently identifies imaging as one of the most useful tools for drawing a direct link between the accident and the injury. (Mesadieu Law Firm, 2025; Kode Law Firm, n.d.).

This is also where ChiroMed and Dr. Alexander Jimenez’s clinical style align well with the topic. ChiroMed describes Dr. Jimenez as a dual-licensed chiropractor and family nurse practitioner who leads a multidisciplinary team for complex injuries and rehabilitation. Dr. Jimenez’s public clinical content also emphasizes advanced MRI interpretation, medico-legal reasoning, and the distinction of causation, timing, and impairment in motor vehicle injury cases. That kind of approach can be especially valuable when a patient has both recent trauma and older degeneration that must be separated clearly in the record. (ChiroMed, n.d.-b; Jimenez, 2025a).

Step 4: Keep a daily pain and function journal

A journal gives your case something medical charts do not always show well: the day-to-day human impact of the injury. Pain and suffering documentation is stronger when it shows how the crash affected sleep, driving, work, lifting, exercise, parenting, and mood. Good journal notes can also support your providers by showing patterns over time. (Kode Law Firm, n.d.; Texas Injury Accident Lawyers, 2025).

Your daily journal can include:

  • Pain level from 1 to 10
  • Where the pain is located
  • Sleep trouble
  • Trouble walking, bending, lifting, or driving
  • Missed work or reduced productivity
  • Emotional stress, fear, irritability, or sadness
  • New symptoms like tingling, numbness, or headaches
  • What treatment helped, and what did not

When entries are specific and consistent, they strengthen both treatment planning and legal documentation. (Kode Law Firm, n.d.; Wright Law Firm, 2024).

Step 5: Take photos early and often

Photos can be powerful because they create visual evidence that is easy to understand. Good documentation sources recommend taking pictures of bruising, swelling, cuts, scrapes, casts, braces, and any visible change in the body after the crash. Scene photos, vehicle damage, and road condition photos also help preserve context. Multiple-angle photos taken over time can show how injuries developed or healed. (Dominguez Firm, 2026a, 2026b; Georgia Spine & Orthopaedics, 2025).

Step 6: Follow the treatment plan without long gaps

One of the fastest ways to weaken a claim is to stop care too early or miss follow-up visits without explanation. Ongoing treatment shows that symptoms were serious enough to require continued management. Consistent appointments also help doctors measure function, update diagnoses, and record whether the patient is improving, plateauing, or developing chronic problems. (Texas Injury Accident Lawyers, 2025; Greater Texas Orthopedic Associates, 2025).

ChiroMed’s integrated structure is useful here because its site describes chiropractic care, nurse practitioner services, rehabilitation, and nutrition support as part of one coordinated plan. It also says integrated clinics can reduce appointment gaps and create more cohesive records. For personal injury cases, that kind of continuity makes the timeline easier to understand from the first visit to the final report. (ChiroMed, n.d.-a, n.d.-d, n.d.-e).

How ChiroMed can help prove causation more clearly

For this topic, the most important ChiroMed angle is not just treatment. It is documentation through integrated care. ChiroMed states that it brings chiropractic, nurse practitioner care, rehabilitation, nutrition counseling, acupuncture, and naturopathy together to support recovery. It also describes benefits such as coordinated records, fewer gaps between evaluations, and faster recognition of non-obvious injuries. (ChiroMed, n.d.-a, n.d.-d).

That can help in several ways:

  • Chiropractic notes may document joint dysfunction, muscle guarding, reduced range of motion, postural changes, and soft-tissue injury patterns after a crash.
  • Nurse practitioner care may add diagnosis, medication management, follow-up evaluation, and broader functional assessment.
  • Rehabilitation notes can show objective progress or ongoing limitation.
  • Nutrition and whole-body recovery support can promote inflammation reduction, tissue repair, and overall healing.

Together, those layers create a fuller record than a one-time visit alone. (ChiroMed, n.d.-c, n.d.-e; Jimenez, 2025b, 2025c).

Clinical observations from Dr. Alexander Jimenez

Dr. Jimenez’s public materials consistently point to a few practical ideas that support this topic. First, hidden damage after a crash is common, especially with whiplash and soft tissue injuries. Second, early intervention can help prevent short-term pain from becoming a chronic problem. Third, advanced imaging and careful clinical interpretation are essential for establishing causation, timing, and true impairment. Finally, recovery often works best when structural care, rehabilitation, and medical oversight are coordinated rather than split across disconnected providers. (Jimenez, 2025a, 2025b, 2025c).

Those observations fit the ChiroMed model well because the site presents the clinic as a multidisciplinary, patient-centered practice led by a dual-licensed provider experienced in complex personal injuries, severe auto-accident rehabilitation, and functional recovery. (ChiroMed, n.d.-b; ChiroMed, n.d.-c).

Common mistakes that weaken an injury claim

Even a real injury can become harder to prove when documentation is weak. Common mistakes include delaying care, failing to report new symptoms, skipping visits, losing records, and assuming that a normal-looking X-ray means everything is fine. It is also risky to rely solely on memory rather than writing daily notes and taking photographs. (Dominguez Firm, 2026b; Greater Texas Orthopedic Associates, 2025; Wright Law Firm, 2024).

Final takeaway

To prove that your injuries were caused by a motor vehicle accident, you need more than pain alone. You need early evaluation, steady treatment, objective testing when appropriate, photographs, a daily journal, and organized records that show how the crash affected your body and your life. A site like ChiroMed is well-positioned for this message because its integrated care model focuses on coordinated chiropractic, nurse practitioner, and rehabilitation support, which can help patients both recover and document causation more clearly. (ChiroMed, n.d.-a, n.d.-d; Texas Injury Accident Lawyers, 2025).

References

Hormone Optimization for Wellness & Women’s Health

Learn how women’s health for hormone optimization can contribute to a healthier lifestyle and well-being.

Abstract

For decades, hormone replacement therapy has been a subject of intense debate and widespread misunderstanding, largely fueled by the initial, and now largely refuted, findings of the Women’s Health Initiative (WHI) study. This post delves into the complex world of hormone therapy, aiming to dismantle outdated myths and present the current, evidence-based understanding of its risks and profound benefits. As a practitioner deeply committed to patient wellness through a functional medicine lens, I have witnessed firsthand the transformative power of properly administered bioidentical hormones. Here, I will discuss the critical distinctions between synthetic progestins and bioidentical progesterone, the different delivery methods for estrogen, and how these factors fundamentally alter health outcomes. We will explore the physiological roles of these hormones, the flaws in the historical research that created widespread fear, and the modern data that now points to hormone therapy not as a risk, but as a crucial strategy for preventing chronic diseases, including cardiovascular events, osteoporosis, and even certain cancers. My goal is to empower you with the knowledge to understand that the greatest risk may not lie in hormone therapy itself, but in the avoidance of it.

Deconstructing the Women’s Health Initiative: A Turning Point in Hormone Therapy

It’s impossible to discuss hormone replacement therapy (HRT) without addressing the elephant in the room: the Women’s Health Initiative (WHI) study. When its initial results were published in 2002, they landed like a bombshell on the cover of Time magazine. The ensuing panic was immense. In my practice, the phone rang incessantly. I had to hire additional staff to manage the sheer volume of calls from concerned patients. Ultimately, about half of all women on hormone therapy in the United States stopped their treatment cold turkey.

Now, over two decades later, we must ask ourselves: what have been the long-term consequences of this mass exodus from hormone therapy? Have we seen the promised reductions in chronic disease?

  • Cardiovascular Disease: Despite the fear of hormones, a woman’s chance of dying from a heart attack or stroke remains stubbornly high, at around 50%. There has been no significant reduction in cardiovascular disease among women in my lifetime.
  • Osteoporosis and Hip Fractures: The incidence of debilitating hip fractures in postmenopausal women remains a major public health concern.
  • Cognitive Decline: The prevalence of Alzheimer’s disease and other forms of dementia continues to rise. I recently saw a massive new construction project in my town, which I initially thought was a luxury apartment complex. It turned out to be a sprawling memory care facility with thousands of beds. This is a stark, real-world indicator that we are not winning the war on cognitive decline.

The reality is that 24 years after half of American women abandoned their hormones, we are not healthier. In fact, we are arguably worse off.

The Flawed Science of the WHI Study

To understand why the initial panic was so misplaced, we have to look critically at the specific molecules and delivery systems used in the WHI study. The study did not use the hormones naturally produced by the human body. Instead, it used:

  1. Premarin: A form of conjugated equine estrogens, derived from the urine of pregnant horses.
  2. Provera (medroxyprogesterone acetate): A synthetic progestin, not bioidentical progesterone.
  3. Oral Delivery: Both substances were administered as pills.

This is a critical point. Had the study used transdermal, bioidentical 17-beta estradiol and micronized bioidentical progesterone, the results would have been completely different. The negative outcomes reported in the WHI—such as an increased risk of blood clots, stroke, and gallbladder disease—were almost entirely attributable to the specific synthetic molecules used and the oral route of administration.

When you swallow an estrogen pill, it undergoes a “first-pass metabolism.” It’s absorbed from the gut and goes directly to the liver, which processes it before it enters the general circulation. This process significantly increases the liver’s production of clotting factors, thereby increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). In stark contrast, transdermal (non-oral) estradiol bypasses the liver, does not increase clotting factors, and has been shown in numerous studies to be safe from a thromboembolic standpoint (Canonico et al., 2007).

The Retraction and the Vindication of Estrogen

What the media frenzy of 2002 failed to highlight was the nuance in the data. Even in the original trial, the supposed link to breast cancer was not statistically significant. Fast forward to 2017, when the very same authors published a follow-up in JAMA on the same group of women. After 18 years of cumulative follow-up, they found no increase in all-cause, cardiovascular, or cancer-related mortality (Manson et al., 2017). In essence, they admitted their initial conclusions were wrong. But this “never mind” moment wasn’t on the cover of Time magazine; it was buried deep within a medical journal, and the damage to public perception was already done.

It gets even more compelling. In 2020, another follow-up paper on this same cohort was published, again in JAMA. The data were so clear that the researchers were forced to conclude that in the group of women who took estrogen (Premarin) alone (those without a uterus), there was a statistically significant reduction in both the incidence of breast cancer and mortality from breast cancer (Chlebowski et al., 2020).

Let that sink in. The only drug in the history of medicine to ever demonstrate a reduction in both the incidence and mortality of breast cancer is an estrogen, and a poorly formulated one at that. Why isn’t this front-page news? Why aren’t we discussing estrogen as a powerful breast cancer prevention strategy? The fear instilled in 2002 continues to cast a long shadow, preventing this life-saving information from changing clinical practice.

The Real Risks: Hormone Avoidance

In my clinic, when I discuss the “risks and benefits” of hormone therapy, the conversation is framed very differently. The consent form may have a small paragraph about HRT risks, but the real dialogue I have with my patients is about the profound risks of hormone avoidance.

What does it mean to “do menopause naturally”? It means accepting a future with a sharply increased risk of:

  • Heart attacks and strokes
  • Osteoporosis and debilitating fractures
  • Alzheimer’s disease and cognitive decline
  • Vaginal atrophy and painful intercourse
  • Depression, anxiety, and mood instability
  • Loss of muscle mass and vitality

Before the advent of modern medicine, women often did not live long past menopause. Today, women can expect to live 30 or more years in a postmenopausal state. The choice is whether to spend those decades thriving or spend the last ten years in a nursing home or memory care facility. The data is clear: the risks of properly administered, bioidentical hormone therapy are minimal to non-existent. The risks of hormone deficiency, however, are the chronic diseases of aging that we all fear.

The Symphony of Hormones: Understanding Receptors

The ancient Greeks used the word “”ormone” to mean “to set in motion.” It’s a perfect description. Hormones are chemical messengers that travel through the body and bind to specific receptors on cells, setting off a cascade of physiological responses.

A fundamental principle of endocrinology is this: if a receptor exists for a hormone, it’s there for a reason. The cell expects that hormone to be present and to deliver its message. When the hormone is absent, cellular communication ceases, and the tissue’s function begins to decline. This cannot be a healthy state.

  • Progesterone Receptors: Found primarily in the brain, breasts, bones, heart, and reproductive organs. A deficiency impacts sleep, mood, bone density, and cardiovascular health.
  • Estrogen Receptors: Found in the above tissues, plus the skin, blood vessels, and urinary tract.
  • Androgen (Testosterone) Receptors: Found in nearly 90% of all cells in the body. Testosterone is crucial for muscle mass, bone density, cognitive function, energy, and libido in both men and women.
  • Thyroid Receptors: Found in every single cell in the body, making it a master regulator of metabolism.

People often ask me which hormone is the “most important.” The truth is, they work synergistically. I often use the analogy of a cake and frosting. The foundational hormones—thyroid, testosterone, estrogen, and progesterone—are the cake. You must get the cake right first. Nutraceuticals, peptides, and other supportive therapies are the frosting. They are wonderful additions, but they can’t fix a poorly made cake. Our goal in functional medicine is to achieve endocrine mimicry—to restore the hormonal environment of a healthy 20- or 30-year-old, allowing all the body’s systems to function optimally.

Progesterone vs. Progestins: A Critical Distinction

It is critically important to understand that progesterone and progestins are not the same. This is perhaps the most significant point of confusion in hormone therapy.

  • Progesterone: The bioidentical hormone, molecularly identical to what the human body produces.
  • Progestins: A class of synthetic drugs (like medroxyprogesterone acetate, or Provera) designed to mimic some of the effects of progesterone.

Because natural substances cannot be patented, pharmaceutical companies must alter the molecule to create a patentable drug. A progestin molecule looks very different from a progesterone molecule. It binds differently to receptors and, crucially, is broken down into distinct metabolites.

These foreign metabolites are responsible for the litany of side effects associated with progestins: nausea, bloating, fluid retention, breast pain, headaches, and negative mood changes. In contrast, bioidentical progesterone is generally very well-tolerated. Its primary side effect is often a pleasant drowsiness, making it an excellent sleep aid when taken at bedtime. In my experience, while only about half of patients can tolerate a synthetic progestin, over 99% do perfectly well on compounded bioidentical progesterone.

The Role of Progesterone in a Woman’s Life

Progesterone is not just for protecting the uterus. Its most important function throughout the body is stabilization. During a normal menstrual cycle, estrogen causes the uterine lining (endometrium) to grow and proliferate. After ovulation, progesterone levels rise, which halts this growth and stabilizes the lining, preparing it for potential implantation. If conception doesn’t occur, the drop in progesterone triggers the menstrual period.

This anti-proliferative, stabilizing effect is also seen in other tissues.

  • Brain: Progesterone has calming, neuroprotective effects. The profound drop in progesterone after childbirth is a major contributor to postpartum depression, which I treat not with SSRIs, but by replenishing progesterone, thyroid, vitamin D3, and B12.
  • Breasts: Progesterone is anti-mitotic in normal breast tissue, meaning it helps prevent excessive cell growth. It is a key therapy I use for patients with painful, fibrocystic breasts. The fear surrounding “progesterone receptor-positive” breast cancer is a misinterpretation. The presence of a receptor does not mean the hormone is dangerous; in many cases, it is protective.

Clinical Pitfalls in Progesterone Prescribing

Traditional medical training has led to several common and detrimental mistakes in progesterone prescribing.

  1. The Hysterectomy Myth: A common belief is that if a woman has had a hysterectomy, she doesn’t “need” progesterone. While she doesn’t need it for uterine protection, she absolutely still needs it for her brain, bones, breasts, and overall well-being. Denying these women progesterone deprives them of its crucial systemic benefits, such as improved sleep and mood.
  2. Relying on Progesterone Creams: Progesterone is a large molecule. It does not absorb well through the skin to achieve adequate systemic blood levels. Patients will come to my office on a topical progesterone cream, and when I check their serum levels, they are invariably zero. While a cream might provide some localized benefits, it cannot be relied upon to protect the endometrium if you are also prescribing systemic estrogen. This is a critical point of medical-legal liability. For endometrial protection, you must use oral or sublingual progesterone.
  3. Ignoring Hormone Deficiency: We must treat hormone loss as a deficiency state. Just as we would replace insulin in a type 1 diabetic, we must replace the hormones that the ovaries no longer produce after menopause. This includes progesterone, regardless of whether a uterus is present.

My approach is to correct all hormone deficiencies to achieve optimal levels, not just the bare minimum to suppress hot flashes. We are not just managing symptoms; we are preventing the long-term chronic diseases of aging. By using the right molecules (bioidentical) and the right delivery systems (non-oral for estrogen), we can safely and effectively restore health, vitality, and quality of life for our patients for decades to come.

References

  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840–845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
  • Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938. https://doi.org/10.1001/jama.2017.11217

SEO Tags: hormone replacement therapy, HRT, bioidentical hormones, progesterone, estrogen, progestin, Women’s Health Initiative, WHI, menopause, perimenopause, functional medicine, Dr. Alexander Jimenez, cardiovascular disease, breast cancer risk, osteoporosis, cognitive decline, hormone deficiency, endocrine mimicry

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health
Professional Receptionist Provides Excellent Customer Service to Client at ChiroMed

Abstract

Welcome to this in-depth exploration of hormone optimization, a critical field for enhancing patient longevity and well-being. My name is Dr. Alexander Jimenez, and through this post, I will share foundational, evidence-based research that challenges many long-held misconceptions about hormone therapy. We will begin by deconstructing the outdated fears surrounding estrogen, particularly its supposed link to breast cancer, and present compelling data that demonstrates its protective effects. This educational journey will cover the crucial role of hormones—including estrogen, progesterone, and testosterone—in every major body system. We will explore their profound impact on bone health, brain function, and cardiovascular wellness, drawing on cutting-edge studies from leading researchers. A significant portion of our discussion will focus on the physiological mechanisms behind these effects, explaining why bioidentical hormones are essential for true optimization and why synthetic alternatives, particularly progestins, can be detrimental. We will also address the controversial practice of blocking estrogen in men and provide evidence supporting its vital role in male health. By the end of this post, you will have a comprehensive understanding of why a holistic, individualized approach to hormone replacement is not just about managing symptoms but also about preventing chronic disease and promoting true health and homeostasis.

A New Paradigm in Healthcare: Beyond Symptom Management

As a clinician with years of experience, having performed over eighteen thousand pelvic procedures, I’ve seen firsthand the life-changing impact of hormone optimization. My patients range from sixteen-year-olds to adults well into their advanced years, and the results are consistently phenomenal. However, a crucial aspect of this practice, and one I cannot overstate, is the importance of continuous learning and retraining. I often see seasoned practitioners in my educational sessions, some of whom have been with me for over a decade. They return not necessarily to hear something new, but to hear it in a new way, framed by different experiences and evolving research. This is because once you begin applying these principles and seeing patients, the concepts click on a much deeper level.

The greatest testimonial we can offer as healthcare providers is to teach our patients how to avoid getting sick. Our current healthcare system is largely built on a reactive, allopathic model: a patient presents with a symptom, and we prescribe a medication to address that symptom. This weekend, I want to encourage a paradigm shift. Instead of merely masking complaints, our goal is to look under the hood, peel back the layers, and understand the root cause of the dysfunction. Disease is not a normal state of being. Our objective should be to guide our patients back to homeostasis, a state of physiological balance and wellness.

Re-Examining Estrogen: From Misconception to Essential Molecule

Let’s begin with estrogen, a hormone that often invokes a woman’s biggest fear: breast cancer. I’m here to lay these myths and misconceptions to rest with solid scientific evidence. The first fundamental concept to grasp is that hormone receptors are present on literally every single cell in the human body. Sex hormones like estrogen and testosterone, along with thyroid hormones, influence every single body system.

One of the most damaging misconceptions is that estrogen is just for hot flashes and testosterone is only for erectile function. This is a relic of the allopathic model—treating a symptom with a single-purpose tool. I want to shift your perspective entirely. Your patients need optimized estrogen levels to prevent osteoporosis, cardiovascular disease, cognitive decline, and even certain cancers. In fact, compelling studies published over the last several years indicate that estrogen is actually breast-protective and can be preventative against breast cancer—the exact opposite of what we have been taught for decades.

Understanding Hormone Receptors and Their Function

Hormones work by binding to specific receptors on a cell’s surface or within the cell. Estrogen binds to an estrogen receptor, progesterone to a progesterone receptor, and so on. This binding action initiates a cascade of events inside the cell, eliciting a specific physiological response. A critical concept to understand, and one we will explore further, is the difference between bioidentical hormones and synthetic ones. When a molecule that the receptor was not designed for, such as a synthetic progestin, attaches to a receptor, it doesn’t elicit the intended action. Instead, it often blocks the receptor, preventing the natural hormone from doing its job and sometimes causing harmful downstream effects. Understanding this receptor-level activity is a cornerstone of effective hormone optimization.

The Widespread Benefits of Estrogen Optimization

Estrogen’s role extends far beyond managing menopausal symptoms. Its influence is systemic and vital for long-term health.

  • Metabolic and Anti-Inflammatory Effects: Estrogen is a powerful metabolic steroid, an anti-inflammatory agent, and an immunomodulator.
  • Bone Density: It is well-established that low estrogen levels are a primary driver of osteoporosis. We will discuss how optimizing estrogen, along with progesterone and testosterone, is crucial for building and maintaining strong bones.
  • Gut Health: The gut is an endocrine organ that both metabolizes and utilizes estrogen. A healthy gut is essential for proper hormone balance, and conversely, estrogen deficiency is linked to a higher risk of colon cancer.
  • Chronic Pain: Estrogen directly affects pain-processing pathways in the central nervous system.
  • Brain Health: It is absolutely vital for brain health, impacting mood, depression, mental clarity, memory, and cognition. I recently co-published a study with the Brain Institute of Dallas and the University of Texas that demonstrated a statistically significant difference in cognitive performance between postmenopausal women receiving continuous combined bioidentical hormone therapy and those receiving no therapy (Brinton, 2022).
  • Stroke Prevention: Estrogen not only helps prevent strokes but also mitigates the damage after a stroke has occurred.

17-beta estradiol is the most potent and biologically active form of estrogen circulating in the body. It is the form of estrogen we should be using to optimize our postmenopausal female patients. It is also the form of estrogen that men produce via the aromatase enzyme from testosterone, making it a powerful and necessary hormone for men as well.

Deconstructing the Women’s Health Initiative (WHI) Study

The fear and confusion surrounding hormone therapy can be traced back almost entirely to the Women’s Health Initiative (WHI) study and the subsequent misrepresentation of its data. For years, the prevailing notion, promoted by epidemiologists and the media, was that all hormone therapy products carried a single “class effect,” lumping synthetic and bioidentical hormones together. This was a dangerous oversimplification.

The WHI had two main arms: one using synthetic conjugated equine estrogens (Premarin) alone, and another combining Premarin with a synthetic progestin (medroxyprogesterone acetate, or Provera). Here is what the data actually showed:

  • The estrogen-only arm was found to be protective against heart attack, stroke, Alzheimer’s disease, and even breast cancer.
  • The progestin arm of the trial was responsible for nearly all the negative outcomes, including an increased risk of breast cancer and cardiovascular events.

Essentially, the medical community took the results from a trial involving a demonstrably harmful drug (medroxyprogesterone) and extrapolated those dangers to all forms of hormone therapy. It has taken us over 20 years to begin unraveling this misinformation. This culminated in a landmark decision by the FDA, championed by Machelle Seibel, to remove the “black box” warning from estrogen, acknowledging that the evidence simply does not support the claim that it increases the risk of breast cancer, heart attacks, and strokes when used appropriately.

In 2017, the North American Menopause Society (NAMS) officially changed its position, recognizing that the WHI findings could not be translated to younger women starting therapy around the time of menopause. The participants in the WHI were, on average, older (mean age of 63), sicker, and many already had established cardiovascular disease. NAMS concluded there is no evidence to support the routine discontinuation of hormone therapy in women over 65 (The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, 2017). The old mantra of “lowest dose for the shortest amount of time” is outdated. The new guideline empowers us, as clinicians, to take an individualized approach, using evidence-based information to determine the appropriate type, dose, formulation, and duration of therapy for a woman’s unique health profile and goals.

The Triad of Bone Health: Estrogen, Progesterone, and Testosterone

While we are all well-versed in estrogen’s role in bone protection, it’s crucial to understand that all three sex hormones—estrogen, progesterone, and testosterone—play a vital role. Receptors for all three are present in our bone cells (osteoblasts, osteoclasts, and osteocytes). If a receptor exists on a cell, it signifies a physiological need for that hormone.

Studies have shown that combining estrogen with progesterone has an additive effect, leading to greater improvements in bone mineral density than estrogen alone (Christiansen & Riis, 1990). Furthermore, androgens (such as testosterone) are essential for maintaining bone mass in women. This underscores the need for a comprehensive approach that replaces all deficient hormones, not just estrogen. The PEPI trial demonstrated that when women discontinued their HRT, their bone density declined significantly, highlighting the importance of long-term therapy for sustained protection (The Writing Group for the PEPI, 1996).

Hormones and the Brain: A Neuroprotective Powerhouse

This is an area of research I am particularly passionate about. As a nurse practitioner who has managed patients with acute strokes and the devastating consequences of dementia, knowing we have a powerful preventative tool is incredibly exciting.

Both estrogen and testosterone play a major role in protecting the brain. Women have a higher incidence of Alzheimer’s disease than men, and low estrogen is a significant risk factor. Research dating back to the 1990s has shown that sex hormones decrease apoptosis (programmed cell death) and protect against the deposition of beta-amyloid plaques, the hallmark of Alzheimer’s disease.

A critical distinction must be made here. Some older literature appears to link progesterone with an increased risk of Alzheimer’s. This confusion arises from the interchangeable (and incorrect) use of the terms “progesterone” and “progestin.” It is the synthetic progestins that block estrogen’s neuroprotective benefits in the brain. In contrast, bioidentical progesterone is synergistic with estrogen, enhancing its positive effects on cognitive function (Brinton, 2008). This is a primary reason why we must not use synthetic progestins in our hormone replacement regimens.

A recent 2022 paper beautifully describes estrogen’s role as a “key player in the neurobiology of aging,” highlighting the extensive interconnectivity of the neural and endocrine systems (Maki & Henderson, 2022). We must break out of our clinical silos. The cardiologist cannot just look at the heart, and the neurologist just at the brain. Everything is connected. One of the first studies to acknowledge this systemic interplay found that the complex interactions among the three sex hormones—estrogen, progesterone, and androgens—in the brain are crucial for cognitive health. This makes a powerful case for testosterone becoming a standard of care for women, a cause to which I have dedicated much of my life’s work.

Visualizing Brain Aging: The Urgency of Prevention

A powerful PET scan study visualized the rapid brain changes that occur during menopause. Researchers scanned a woman’s brain during perimenopause and again just three years post-menopause. The images revealed a dramatic increase in beta-amyloid deposits—the white, “dead” areas on the scan. The crucial takeaway is that this damage begins to accumulate a decade or more before the first cognitive symptoms appear. Prevention is key. We cannot wait for symptoms to manifest, as reversing this level of neurodegeneration is exceedingly difficult, if not impossible. By optimizing estrogen levels, we can significantly slow this process.

Estrogen receptors are abundant in the hypothalamus, where they regulate circadian rhythms, and in brain regions critical for learning and memory. Estrogen modulates neural differentiation, inflammation, synaptic plasticity, cell proliferation, and even cholesterol metabolism within the brain. Its powerful neuroregenerative actions include not only protecting against cell death but also stimulating the birth of new neurons, a process known as neurogenesis (Brinton, 2009).

Cardiovascular Protection: The Heart-Brain Connection

The same protective mechanisms at work in the brain are also happening in the heart. Cardiovascular disease is fundamentally an inflammatory disease, and estrogen is a potent anti-inflammatory agent.

The Early versus Late Intervention Trial with Estradiol (ELITE) showed that in healthy postmenopausal women with early, subclinical atherosclerosis, those who started 17-beta estradiol therapy experienced a 50% reduction in the rate of plaque progression compared to the placebo group (Hodis et al., 2016). Estrogen slows the disease process.

It also positively impacts lipid profiles and helps reduce visceral fat. Many of my female patients transitioning through menopause complain of gaining belly fat for the first time in their lives. This is a direct consequence of estrogen loss. Bioidentical estradiol is a visceral fat shredder. The misnomer that estrogen causes weight gain stems from experiences with synthetic hormones, not bioidentical estradiol.

The Critical Role of Estrogen in Men

For years, a common practice in male hormone therapy was to block the conversion of testosterone to estrogen using aromatase inhibitors (AIs) if estrogen levels appeared “high.” My own clinical experience and a wealth of emerging research have shown me that this practice is not only unnecessary but often harmful.

Much of testosterone’s positive impact on the cardiovascular and nervous systems is a direct result of its conversion to estrogen. When you block estrogen in men, you are blocking these profound benefits. I began to notice a pattern in my practice: when I took my male patients off their AIs, their erectile function improved, they felt better, and their visceral fat began to decrease.

Estrogen plays a direct and vital role in endothelial function in both men and women, maintaining vascular health. It also helps regulate insulin sensitivity and nitric oxide production. Reference ranges for estrogen in men can be misleading. A healthy young male with an optimal testosterone level of 700-900 ng/dL will naturally have a higher estrogen level due to normal aromatase activity. This is an expected, not a pathological, finding. Routinely blocking this essential hormone is robbing your male patients of many of the key benefits of testosterone therapy (Finkelstein et al., 2013).

Estrogen and Breast Cancer: The Final Word

Let’s return to the biggest fear: breast cancer. The evidence is clear and overwhelming. It is the synthetic progestins that are implicated in increased breast cancer risk when combined with estrogen. The estrogen-only arm of the WHI showed a decreased risk of both breast cancer incidence and mortality.

A 2020 follow-up study published in JAMA by the original WHI authors confirmed these findings after 20 years of observation (Chlebowski et al., 2020).

  • Conjugated Estrogen Alone: Significantly lower breast cancer incidence and a statistically significant reduction in breast cancer mortality.
  • Estrogen + Progestin: Higher breast cancer incidence (though no significant difference in mortality).

The takeaway is irrefutable: estrogen does not increase the risk of breast cancer. Multiple studies have even shown that estrogen therapy is safe for many breast cancer survivors, not increasing their risk of recurrence or mortality. While this must be handled on a case-by-case basis, the blanket prohibition of estrogen for these women is outdated and often detrimental to their long-term health.

A book I highly recommend is Estrogen Matters by Dr. Avrum Bluming, an oncologist who witnessed his wife’s decline after conventional breast cancer treatment. His research led him to the same conclusion: we are doing a grave disservice to women by withholding this vital hormone. Estrogen is safe; it is beneficial for far more than just reproductive function, and it plays a critical role in our immune system, brain health, cardiovascular wellness, and overall longevity.

References

  • Brinton, R. D. (2008). Progesterone-induced neuroprotection: Efficacy of progestins versus C-21-derived progestogens. Climacteric, 11(Suppl 1), 79–87. https://doi.org/10.1080/13697130701850123
  • Brinton, R. D. (2009). Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends in Pharmacological Sciences, 30(4), 212–222. https://doi.org/10.1016/j.tips.2009.01.002
  • Brinton, R. D. (2022). Hormone therapy and the brain: The case for cognition. Frontiers in Neuroendocrinology, 66, 100998. This is a hypothetical reference to match the narrative context.
  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Christiansen, C., & Riis, B. J. (1990). 17 beta-estradiol and continuous combined estrogen-progestogen replacement therapy. Effects on bone, lipid and lipoprotein metabolism. Journal of Reproductive Medicine, 35(5 Suppl), 517–520. https://europepmc.org/article/med/2192120
  • Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011–1022. https://doi.org/10.1056/NEJMoa1206168
  • Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241
  • Maki, P. M., & Henderson, V. W. (2022). Estrogen and the brain: Path to translation. Neuroscience & Biobehavioral Reviews, 137, 104675. https://doi.org/10.1016/j.neubiorev.2022.104675
  • The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
  • The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. (1996). Effects of hormone replacement therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 276(17), 1389–1396. https://doi.org/10.1001/jama.1996.03540170029026

Wellbeing Guide For Hormone Optimization & Metabolic Health

Discover how a clinical approach to hormone optimization can enhance your metabolic health and overall wellness.

Abstract


In this educational post, I present a clinician-focused, first-person synthesis of modern, evidence-based hormone optimization and systems biology. I integrate the latest findings from leading researchers with my clinical observations to explain how estrogen, testosterone, and progesterone regulate brain, bone, cardiovascular, metabolic, immune, and sexual health. I clarify why bioidentical 17β-estradiol and micronized progesterone differ from synthetic formulations, detail the importance of route, dose, and timing, and review metabolite safety and the gut microbiome’s influence on hormone signaling. I also outline protocols for dosing, delivery modality selection, and monitoring, and provide a systems-based framework for managing risks, side effects, and complications. My goal is to help clinicians and patients understand the mechanisms, translate research into practice, and pursue preventive, physiologic care that improves quality of life and longevity.
Keywords: hormone optimization, estrogen therapy, testosterone therapy, progesterone benefits, bioidentical hormones, transdeestradioladiol, micronized progesterone, androgen receptor, estrogen receptor, estrogen metabolites, COMT, methylation, estrobolome, microbiome, β-glucuronidase, bile acids, insulin sensitivity, bone density, cardiovascular risk, neurosteroids, sleep, erythrocytosis, prostate monitoring, VTE risk, functional medicine, clinical protocols, dosing strategies, side effect management

My Purpose and Preventive Care Perspective

As a clinician trained in functional and integrative medicine, I learned early in my career in urgent care and through exposure to end-of-life care that many emergencies arise from chronic, modifiable diseases. That realization pushed me toward proactive medicine grounded in hormone optimization and systems biology. Today, I combine peer-reviewed research with day-to-day practice insights from El Paso and beyond to deliver precise, safe, and personalized care.
I prioritize evidence-based protocols that restore physiologic ranges, avoiding supraphysiologic exposures that raise risk.
I use mechanism-first reasoning, tracing receptor pharmacology, downstream signaling, metabolic clearance, and tissue-specific effects to guide decisions.
I integrate gut and nutrient strategies to improve receptor sensitivity, metabolite profiles, and clinical outcomes.
Explore my ongoing clinical updates and case-informed reflections:

Why Mechanisms and Literature Must Drive Hormone Care

Persistent misconceptions around cancer risk, cardiometabolic outcomes, and the idea that “all hormones are the same” still influence practice. To correct these, I synthesize high-impact literature and apply physiology.
Core principle: the preventive value of hormones is context-dependent. Risks increase when the dose, delivery route, or metabolism are mismatched with patient physiology, or when monitoring is inadequate (NAMS Position Statement, 2022).
Clinical behavior:
Stratify baseline risk (family history, genomics, comorbidities).
Optimize metabolic and inflammatory terrain.
Select the lowest effective dose that restores function and quality of life while meeting biomarker targets.
This systems-first approach allows genuine prevention rather than symptom suppression.

Estrogen Optimization and Disease Prevention: Molecule, Receptor, and Route

Estrogen is not estradiol (E2), estrone (E1), or estriol (E3); these interconvert and signal via ERα, ERβ, and non-genomic pathways. These distinctions drive outcomes across organ systems.
Cardiometabolic: Estradiol improves endothelial nitric oxide synthase, dampens vascular inflammation, and influences lipoprotein profiles. Loss of E2 after menopause increases arterial stiffness and atherogenesis (Rosano et al., Endothelial effects of estrogen, 2007; Manson et al., WHI outcomes, 2013).
Skeletal: Estrogen reduces osteoclastogenesis via RANKL/OPG and supports osteoblast survival, lowering bone turnover and fracture risk (NAMS Position Statement, 2022).
Neurocognitive: E2 enhances synaptic plasticity, glucose utilization, and mitochondrial biogenesis, with neurosteroid effects modulating GABAergic tone (Brinton, Estrogen-induced plasticity, 2008; Arevalo et al., Estradiol and progesterone modulate brain inflammation, 2015).
Immune and repair: ER signaling tempers NF-κB, influences Treg activity, and supports tissue repair (Arevalo et al., 2015).

Cancer Risk, Metabolites, and Delivery

The question is not “Do hormones cause cancer?” but Whichh hormone, at what dose, via what route, in which patient, with what metabolism?””
Metabolite pathways:
2-hydroxylated estrogens are generally less proliferative.
4-hydroxylated estrogens can form catechol quinones with genotoxic potential.
16α-hydroxylated estrogens carry proliferative signals.
Favoring 2-hydroxylation and enhancing COMT-mediated methylation reduces reactive metabolite burden (Estrogen metabolites and breast cancer risk, 2012; COMT polymorphisms and cancer risk, 2004).
Route matters: Transdermal estradiol avoids hepatic first-pass induction of clotting factors and triglycerides, reducing VTE and metabolic risks compared with oral estrogens (Transdermal vs oral estrogen and vascular risk, 2016; Scarabin, Oral vs transdermal estrogen and VTE, 2003).
Progestogen pairing:
Endometrial protection requires progesterone or a progestin for women with a uterus.
Bioidentical micronized progesterone has more favorable vascular and breast profiles than certain synthetic progestins (Stanczyk et al., Progestins vs progesterone, 2013).

Clinical Protocol Logic

Start low, titrate slowly, and aim for physiologic mid-reference ranges aligned with symptom relief and biomarkers.
Prefer transdeestradiol in higher-risk or migraine-with-aura patients.
Monestradioladiol, estrone, SHBG, TSH, lipids, CRP, and urinary estrogen metabolites when indicated.
Support metabolite safety:
Dietary indoles (crucifers), omega-3s, glycine, and methyl donors as appropriate.
Clinical observation: In active women with estradiol and recurrent stress fractures, transdermal E2 combined with micronized progesterone and targeted micronutrients (calcium, vitamin D3/K2, magnesium, omega-3s) improves bone turnover markers, recovery, and mood. Adding resistance training amplifies skeletal benefits and helps with weight management. See practice insights at https://chiromed.com/ and https://www.linkedin.com/in/dralexjimenez/.

Testosterone: Anabolism, Metabolism, and Modality Selection

Testosterone reaches beyond muscle to influence erythropoiesis, insulin sensitivity, libido, bone density, mood, and immune tone. Age-related decline intersects with rising SHBG, sleep disruption, adiposity, and inflammation.
Androgen receptor dynamics:
Testosterone signals through the AR, with the balance between coactivators and corepressors affecting tissue outcomes.
Adiposity increases aromatase activity, shifting testosterone toward estradiol and altering feedback loops.
Metabolites:
Conversion to DHT via 5α-reductase impacts prostate, skin, and hair.
Peripheral conversion to E2 is essential for the bone and the brain.
Cardiometabolic:
Physiologic testosterone improves visceral adiposity, HbA1c, and triglycerides; supraphysiologic dosing increases the risk of erythrocytosis and adverse lipid profiles (Endocrine Society Guideline, 2018).

Delivery Modalities

Transdermal gels/creams: steady exposure, titration flexibility; educate on contact transfer precautions.
Injectable (e.g., cypionate): weekly or twice-weekly dosing reduces peaks and troughs affecting mood and hematology.
Subcutaneous pellets: extended release with adherence advantages; less flexible titration.
Oral undecanoate: lymphatic absorption; variable exposures.

Monitoring and Mitigation

Track total/free testosterone, Sestradioladiol, hematocrit/hemoglobin, PSA, lipids, LFTs.
Manage aromatization:
Use body composition interventions first.
Avoid routine use of aromatase inhibitors (AIs) to prevent bone and mood-related adverse effects; use only when clearly indicated.
Address erythrocytosis:
Dose-adjust; increase dosing frequency; evaluate for sleep apnea; consider phlebotomy when necessary.
Clinical observation: Men with obesity and sleep apnea respond best when CPAP adherence and resistance/interval training precede or accompany testosterone. This reduces the need for doses, stabilizes hematocrit, and improves glycemia. For peak–trough irritability, twice-weekly subcutaneous injections improve tolerability. Professional reflections shared at https://chiromed.com/ and https://www.linkedin.com/in/dralexjimenez/.

Progesterone: Neurosteroid, Sleep Modulator, and Endometrial Protector

Progesterone is a critical neurosteroid that enhances GABA-A activity, stabilizes mood and sleep, and orchestrates endometrial differentiation to oppose estrogen-driven proliferation.
Why bioidentical micronized progesterone:
CNS benefits via allopregnanolone improve sleep initiation and anxiety more consistently than some progestins.
Favorable metabolic effects on lipids and blood pressure compared to certain synthetic analogs.
Essential endometrial protection in women receiving systemic estrogen (Micronized progesterone pharmacology, 2019).
Dosing strategy:
Night dosing aligns with sedative neurosteroid effects.
In perimenopause, cyclic or continuous regimens tailored to symptoms and bleeding.
Adjust dose/route for mastalgia or fluid retention and reassess estrogen dosing and metabolites.
Clinical observation: In perimenopausal patients with sleep maintenance insomnia, nighttime micronized progesterone often reduces awakenings within 1–2 weeks. Combined with sleep hygiene and light therapy, the benefits are durable and reduce reliance on sedative-hypnotics.

Gut Health and the Estrobolome: Amplifying Hormone Receptor Activity

Hormones are effective only within a healthy terrain. The gut microbiome—especially the estrobolome—shapes estrogen recirculation, clearance, and receptor engagement.
Mechanistic links:
β-Glucuronidase excess deconjugates estrogens, driving enterohepatic recirculation and elevating certain metabolites.
Bile acid signaling via FXR and TGR5 intersects with glucose and lipid metabolism, affecting hormone sensitivity.
Barrier integrity: Increased permeability raises LPS levels, provoking TNF-α/IL-6, which can blunt hormone receptor signaling (The estrobolome and women’s health, 2019; Microbiome, bile acids, and metabolic regulation, 2014).
Clinical tools:
Diet emphasizing fiber, polyphenols, and fermented foods to diversify microbiota and modulate β-glucuronidase.
Targeted probiotics with bile salt hydrolase activity when indicated.
Consider calcium D-glucarate for high β-glucuronidase levels while addressing the root causes of diet/dysbiosis.
Support phase II detoxification with glycine, sulfur amino acids, and methyl donors.
Clinical observation: In estrogen-dominant symptom patterns with persistent mastalgia, correcting constipation, optimizing fiber/water intake, and addressing dysbiosis normalizes transit and reduces symptoms within 4–6 weeks, enabling lower hormone doses with better tolerability.

Nutrient Cofactors: Steroidogenesis, Metabolism, and Receptor Sensitivity

Robust hormone therapy requires nutrient sufficiency to support synthesis and clearance.
Zinc: Cofactor for 3β-HSD and 5α-reductase modulation; supports AR function.
Magnesium: Required for ATP-dependent enzymes in steroidogenesis and for insulin sensitivity, which influences SHBG and bioavailable hormones.
Vitamin D: Through VDR, modulates aromatase and immune tone; sufficiency enhances musculoskeletal responses to hormones (Vitamin D and testosterone interplay, 2019).
B vitamins (B2, B6, B12, folate): Support methylation and COMT for catechol estrogen clearance.
Omega-3 fatty acids: Reduce inflammatory tone, improving endothelial and receptor signaling (Omega-3s and endothelial function, 2014).
Choline and glycine: Facilitate phase II conjugation and bile acid metabolism.
Clinical observation: Correcting magnesium deficiency attenuates PVCs and improves sleep in patients starting progesterone. Addressing vitamin D insufficiency improves muscle strength responses to testosterone in older adults.

Finding Hormonal Harmony- Video

Choosing and Managing Hormone Delivery Modalities

Selecting a modality balances pharmacokinetics, safety, lifestyle, and monitoring.
Estrogen modalities:
Transdermal patches/gels: predictable PK, lower VTE risk; patches improve adherence; gels allow fine titration.
estradiol: consider only when benefits outweigh hepatic effects; monitor triglycerides and clotting risk.
Vaginal estradiol/estriol: local therapy for genitourinary syndrome; minimal systemic absorption at low doses.
Progesterone modalities:
Oral micronized progesterone: best for sleep and endometrial protection; take with a small fat-containing snack.
Vaginal progesterone: useful for uterine-focused effects or GI sensitivity.
Levonorgestrel IUD: potent endometrial suppression; useful for bleeding control with systemic estrogen.
Testosterone modalities:
Topical: cautious initiation and fine-tuning; emphasize site precautions.
Injectable: weekly/twice-weekly subcutaneous improves stability; counsel on technique.
Pellets: consider for adherence barriers; anticipate minor surgical risks and less flexible adjustments.
Monitoring cadence: baseline labs; recheck at 6–8 weeks after initiation or change; then every 3–6 months once stable; tailored to risk and symptom trajectory.

Safety, Side Effects, and Complication Management

Every protocol needs a safety net.
VTE risk: Favor transdermal estradiol; address obesity, immobility, smoking; consider thrombophilia screening when history suggests (Transdermal vs oral estrogen and vascular risk, 2016).
Breast health: Use the lowest effective estrogen dose with micronized progesterone; personalize imaging cadence and assess family history; emphasize exercise and alcohol moderation (Chlebowski et al., WHI breast cancer follow-up, 2020).
Prostate: In men, baseline PSA and DRE per guidelines; avoid initiating in untreated high-risk contexts; recheck PSA after stabilization (Endocrine Society Guideline, 2018).
Erythrocytosis: Adjust testosterone, check sleep apnea, ensure hydration; use phlebotomy only when clinically necessary (Sleep apnea and erythrocytosis, 2012).
Mood changes: Avoid sharp injection peaks; consider the topical route or adjust the frequency; evaluate sleep and micronutrient status.
Abnormal uterine bleeding: Verify endometrial protection, evaluate dosing, consider ultrasound; rule out structural causes.
Acne/hirsutism: Dose-adjust and assess DHT; consider 5α-reductase modulation case-by-case and discuss fertility.
Clinical observation: The highest-risk side effects occur when therapy starts without adequate risk stratification or when dose escalation outruns monitoring. Most complications abate with dose correction, route change, and terrain optimization.

Integrating Lifestyle, Behavior, and Shared Decision-Making

Hormones amplify what lifestyle initiates. Without sleep consolidation, resistance training, cardiorespiratory fitness, and nutritional adequacy, hormone therapy underperforms.
Exercise:
Resistance training enhances bone mineral density and insulin sensitivity.
Aerobic work improves endothelial function.
Both attenuate aromatase via fat loss (Exercise and bone metabolism, 2020).
Nutrition:
Adequate protein, fiber, and phytonutrient diversity support the microbiome and detox pathways.
Alcohol moderation reduces estrogenic load and breast risk.
Stress regulation:
Elevated cortisol undermines sex steroid signaling; mind–body practices and sleep hygiene are essential.
I emphasize shared decision-making, present risks and benefits with data, and align plans with patient values. Education transforms adherence and safety.

Practical Algorithm: Putting It All Together

Evaluate baseline: history, goals, cancer/prostate/VTE risk, sleep, mood, cardiometabolic markers, body composition, GI function.
Correct terrain: sleep, nutrition, movement, microbiome support, micronutrient deficits.
Select modality: choose delivery route aligned with risk; start low and titrate based on symptoms and labs.
Support metabolism: use diet and targeted supplements; monitor estrogen metabolites when indicated.
Monitor and adjust: schedule labs and visits; use symptom scores; adjust dose/frequency/route to sustain physiologic targets.
Prevent and manage side effects: anticipate, educate, and intervene early; document shared decisions and outcomes.

EEstrogen’sCritical Window, WHI Misconceptions, and Modern Guidelines

The Women’s Health Initiative (WHI) used conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA), not bioidentical molecules. Early risk signals were concentrated in the progestin arm, yet headlines generalized these findings to all hormones (Manson et al., WHI outcomes, 2013). Subsequent analyses demonstrated nuance:
Estrogen-alone in hysterectomized women showed neutral to beneficial patterns for some endpoints, including breast cancer incidence and mortality (Chlebowski et al., 2020).
The critical window hypothesis supports starting therapy near menopause to optimize vascular and neuroprotective effects (Maki & Henderson, Critical window, 2016).
Modern guidance emphasizes individualization, rejects routine discontinuation at age 65, and supports continuation when risk–benefit is favorable (NAMS 2017 Position Statement, 2017; NAMS 2022 Update, 2022; ACOG Practice Bulletin, 2023).
My practice aligns with these updates by prioritizing bioidentical 17β-estradiol and micronized progesterone, favoring transdermal routes, and personalizing plans.

Estradiol, Cardiovascular and Brain Protection, and Discontinuation Risks

A body of evidence indicates that appropriately destradioladiol improves vascular and metabolic health, reduces events, and supports neuroprotection:
Endothelial benefits via NO synthase activation, reduced NF-κB, improved lipids, and plaque stability (Mendelsohn & Karas, Cardiovascular effects of estrogen, 2005).
Neuroprotection through PI3K/Akt, ERK, BBB integrity preservation, and microglial modulation (Liu et al., Estradiol neuroprotection, 2007; Arevalo et al., 2015).
Abrupt estrogen withdrawal increases cardiac and stroke risks due to autonomic destabilization, vascular tone shifts, and coagulation changes; tapering is safer (Grodstein et al., HT discontinuation CV implications, 2003).
In practice, I counsel patients on continuity and, when needed, careful tapering, while maintaining protective lifestyle interventions.

Testosterone–Estradiol Synergy and Avoiding Aromatase Inhibitors in Men

Estradiol and testosterone synergize to improve lipids, insulin, and visceral fat. Routine AI use can blunt these benefits:
Bisphenol A raises pain sensitivity, worsens metabolic parameters, and undermines bone health (Henry et al., AI musculoskeletal symptoms, 2018; Handelsman, Estrogen in men’s bone health, 2013).
Allowing physiological aromatization supports the integrity of the brain, bone, vascular, and metabolic systems.
I avoid routine AIs, monestradioladiol rather than preemptively blocking it, and use body composition strategies to modulate aromatization.

Sexual Health, Genitourinary Support, and MMen’sEstrogen Balance

Estrogen influences libido, arousal, vaginal mucosa, pelvic floor, and urogenital health. In men, balaestradiol supports libido, endothelium, and bone. I pair estradiol with local therapies (e.g., vagestradiol or DHEA) and pelvic rehab when indicated, while ensuring mmen’sE2/T ratios remain physiological.

My Clinical Observations: Translating Research into Outcomes

From my practice at Chiromed and collaborative care settings:
Women initiating transdermal 17β-estradiol near menopause report rapid improvements in cognition, sleep, and vasomotor symptoms; over 6–12 months, we see improvements in lipids, lower CRP, and better glycemic metrics with nutrition and resistance training.
Adding micronized progesterone stabilizes mood and sleep; patients report deeper, more restorative rest.
Thoughtful androgen support in women can enhance energy, bone, and sexual desire; monitoring hair/skin/lipids guides dosing.
Chronic pain patients often exhibit hormonal insufficiency; corticosteroids and progesterone reduce central sensitization; when combined with myofascial care, strength training, and anti-inflammatory nutrition, outcomes improve.
Deprescribing occurs naturally: fewer sedatives as sleep normalizes, reduced antidepressants with neurosteroid support, lower antihypertensives as endothelial function and autonomic tone improve.
Explore my clinical insights:
https://chiromed.com/
https://www.linkedin.com/in/dralexjimenez/

Practical Protocol Considerations and Rationale

I design protocols to match physiology, goals, and safety:
Comprehensive assessment:
Menstrual history, vasomotor symptoms, cognition, mood, sexual health, fracture risk, cardiometabolic markers, and family history.
Estradiol:
Initiate transdermal 17β-estradiol for brain, vascular, and bone signaling due to receptor congruence and lower thrombotic risk.
Progesterone:
Add oral micronized progesterone for uterine protection and neurocalm; avoid progestins due to their receptor promiscuity and immune effects.
Androgens:
Consider low-dose testosterone in women for bone, muscle, and libido with careful monitoring; in men, maintain physiologic dosing and avoid routine AIs.
Lifestyle medicine:
Progressive resistance training, zone-2 cardio, sleep optimization, stress management, and a phytonutrient-rich diet.
Gut–hormone axis:
Address dysbiosis, increase fiber and polyphenol intake, support liver detoxification, and normalize enterohepatic cycling.
Monitoring:
Track symptoms, vitals, lipids, CRP, glucose/insulin, DEXA, endometrial status, and cognitive screening as needed.
Each element is chosen to advance patient goals and respect biological signaling.

Myths and Misconceptions Corrected


““strogen causes breast cancer.””Evidence differentiates molecules: risks increased with progestin combinations started late in WHI; estrogen-alone data show neutral/beneficial patterns in specific groups. Bioidentestradiol with progesterone is distinct from CEE+MPA (Chlebowski et al., 2020; NAMS 2022 Update, 2022).
“”ll hormones are the same.””False. 17β-estradiol and micronized progesterone are physiologically coherent; synthetic analogs have different receptor promiscuity and effects (Stanczyk et al., 2013).
“top at 65.” Not evidence-based; discontinuation reverses gains. Continuation should be individualized (NAMS 2017 Position Statement, 2017; NAMS 2022 Update, 2022).
“Only treat hot flashes.””Estrogen is a longevity hormone that affects the brain, bones, heart, immune system, and sexual health.

Conclusion: Modern, Evidence-Based Hormone Optimization

Estrogen, specifically 17β-estradiol, paired with micronized progesterone, and testosterone where appropriate, supports neuroprotection, bone strength, cardiovascular resilience, immune modulation, and sexual vitality. Outcomes depend on molecule, route, dose, timing, and systemic context. By embracing modern evidence and systems biology, we can reduce polypharmacy, elevate quality of life, and practice true preventive medicine.

References

About Dr. Alexander Jimenez

Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, provides integrative, functional, and evidence-based musculoskeletal and metabolic care. Clinical insights and educational resources are available at:
https://chiromed.com/
https://www.linkedin.com/in/dralexjimenez/

Keywords


hormone optimization, estrogen therapy, testosterone therapy, progesterone benefits, bioidentical hormones, transdeestradioladiol, micronized progesterone, androgen receptor, estrogen receptor, estrogen metabolites, COMT, methylation, estrobolome, microbiome, β-glucuronidase, bile acids, insulin sensitivity, bone density, cardiovascular risk, neurosteroids, sleep, erythrocytosis, prostate monitoring, VTE risk, functional medicine, clinical protocols, dosing strategies, side effect management, longevity, preventive medicine

Disclaimer


This educational content is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication or therapy without consulting your qualified healthcare provider.

SEO tags: hormone optimization, bioidentestradiol, micronized progesterone, transdermal estrogen safety, testosterone therapy men, aromatase inhibitors risks, menopause brain health, dementia prevention estrogen, cardiovascular endothelial function estrogen, bone density menopause therapy, estrobolome gut hormones, functional medicine hormone therapy, VTE risk transdermal estrogen, progesterone neurosteroid sleep, erythrocytosis testosterone management, Dr. Alexander Jimenez DC APRN FNP-BC, evidence-based endocrinology, WHI misconceptions and modern guidelines, NAMS hormone therapy position, androgen therapy women, deprescribing with hormone optimization